

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/64, C07K 7/10	A1	(11) International Publication Number: WO 90/14841 (43) International Publication Date: 13 December 1990 (13.12.90)
(21) International Application Number: PCT/US90/03143 (22) International Filing Date: 4 June 1990 (04.06.90) (30) Priority data: 361,912 6 June 1989 (06.06.89) US 502,273 29 March 1990 (29.03.90) US (71) Applicant: CALIFORNIA BIOTECHNOLOGY INC. [US/US]; 2450 Bayshore Parkway, Mountain View, CA 94043 (US). (72) Inventors: CORDELL, Barbara ; 4051 Ben Lomond Drive, Palo Alto, CA 94306 (US). SCHILLING, James, W. ; 247 Byron Street, Palo Alto, CA 94301 (US). KATUNUMA, Nobuhiko ; 3 Kuramot-cho, Tokushima 770 (JP).		(74) Agents: BOZICEVIC, Karl et al.; Irell & Manella, 545 Middlefield Road, Suite 200, Menlo Park, CA 94025 (US). (81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent)*, DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT USING ALZHEIMER'S AMYLOID POLYPEPTIDES (57) Abstract Pharmaceutical compositions containing a 57 amino acid protease inhibitor and uses for those compositions are taught. The protease inhibitor is referred to as A4i which is associated with Alzheimer's disease. In addition to the A4i protease, other analogs are taught as are pharmaceutical compositions containing such analogs and their uses in treating a variety of abnormalities associated with Kunitz-type basic protease inhibitors. For example, it has been found that pharmaceutical compositions containing A4i protease and analogs thereof inhibit plasmin and trypsin, and also inhibit pancreatic trypsin, alpha-chymotrypsin, tissue kallikrein and serum kallikrein. In that certain diseases are associated with a general release of proteases such as trypsin, chymotrypsin and elastase into the circulatory system pharmaceutical compositions containing A4i and analogs thereof can be used in the management of such diseases.		

* See back of page

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TC	Togo
DK	Denmark			US	United States of America

5

PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT
USING ALZHEIMER'S AMYLOID POLYPEPTIDES

10

15

20

25

Field of the Invention

The invention generally relates to the field of pharmaceutical compositions and methods of using such compositions in order to treat a variety of diseases.

30 More specifically, the invention relates to pharmaceutical compositions containing the A4i protease and to analogs of that protease to treat diseases associated with Kunitz-type basic protease inhibitors.

35 Background Art

The demography of Alzheimer's disease is becoming progressively better understood. It is estimated that over 5% of the U.S. population over 65

SUBSTITUTE SHEET

and over 15% of the U.S. population over 85 are bes t
with this disease (Cross, A.J., Eur J Pharmacol (1982)
82:77-80; Terry, R.D., et al., Ann Neurol (1983)
14:497506). It is believed that the principal cause for
5 confinement of the elderly in long term care facilities
is due to this disease, and approximately 65% of those
dying in skilled nursing facilities suffer from it.

To confound the problem that therapy is at
present a matter of experimentation, diagnosis is also
10 unreliable. There is no straightforward diagnostic
test, and diagnosis is made by a series of evaluations
based on negative results for alternative explanations
for the symptomologies exhibited. Assuming that the
presence of the disease can be assessed accurately after
15 death by autopsies of the brain, current results show
that present diagnostic methods among living individuals
carry an approximately 20% rate of false positives.

It would be extremely helpful in effecting
appropriate care for patients and in developing
20 therapies to have a straightforward assay method for
diagnosing the presence of Alzheimer's disease. The
invention described below provides an approach to this
diagnosis.

Certain facts about the biochemical and
25 metabolic phenomena associated with the presence of
Alzheimer's disease are known. Two morphological and
histopathological changes noted in Alzheimer's disease
brains are neurofibrillary tangles (NFT) and amyloid
deposits. Intraneuronal neurofibrillary tangles are
30 present in other degenerative diseases as well, but the
presence of amyloid deposits both in the interneuronal
spaces (neuritic plaques) and in the surrounding
microvasculature (vascular plaques) seems to be
characteristic of Alzheimer's. Of these, the neuritic
35 plaques seem to be the most prevalent (Price, D.L., et
al., Drug Development Research (1985) 5:59-68). Plaques

SUBSTITUTE SHEET

are also seen in the brains of aged Down's Syndrome patients who develop Alzheimer's disease.

The protein which makes up the bulk of these plaques has been partially purified and sequenced.

5 Plaque-rich brains of deceased Alzheimer's patients have been used as a source to extract an approximately 4.2 kd "core" polypeptide, amyloid plaque core protein (APCP), herein referred to as " β -amyloid core protein." This peptide was designated β -protein by Glenner, G., et al.,
10 [Biochem Biophys Res Commun (1984) 120:885-890]. The amino acid sequence of the amino-terminus has been determined [Glenner, G., et al., Biochem Biophys Res Commun (1984) 122:1131-1135; Masters, C.L., et al., Proc Natl Acad Sci USA (1985) 82:4245-4259] and the amino
15 acid sequences reported by the two groups are identical except that Glenner et al. report a glutamine at position 11 for Alzheimer Disease cerebral vascular amyloid whereas Masters et al. report glutamic acid at position 11. Also, the former authors report that the
20 cerebral vascular amyloid has a unique amino-terminus while the latter authors report that the form found in amyloid plaque cores has a "ragged" amino-terminus -- i.e., peptides isolated from this source appear to be missing 3, 7, or 8 amino acids from the amino-terminus.
25 Both groups have shown that the same peptide is found in the amyloid plaque cores and vascular amyloid of adult Down's syndrome-afflicted individuals and report glutamic acid at position 11.

30 Further studies on the β -amyloid core protein were also conducted by Roher, A., et al., Proc Natl Acad Sci USA (1986) 83:2662-2666 which showed the complete amino acid composition of the protein, and verified that it matched that of no known protein. The compositions obtained were, however, evidently not in agreement with
35 those of Allsop, D., et al., Brain Res (1983) 259:348-

SUBSTITUTE SHEET.

352; nor were they in agreement with those published by Glenner or Masters (supra).

Wong, C.W., et al., Proc Natl Acad Sci USA (1985) 82:8729-8732 showed that a synthetic peptide which was homologous to the first ten amino acids of the β -amyloid core protein described by Masters (supra) was able to raise antibodies in mice and that these antibodies could be used to stain not only amyloid-laden cerebral vessels, but neuritic plaques as well. These results were confirmed by Allsop, D. et al., Neuroscience Letters (1986) 68:252-256 using monoclonal antibodies directed against a synthetic peptide corresponding to amino acids 8-17. Thus, in general, the plaque protein found in various locations of the brain of Alzheimer's patients appears to be similar in immunoreactivity. It is highly insoluble, as shown by the inability to achieve solubilization in many commonly used denaturants such as detergents and chaotropic agents (Masters, supra, Allsop, D., et al., (supra)).

It is believed, by analogy to some other amyloid proteins, that β -amyloid core protein may be formed from a precursor in the peripheral circulatory system or lymphatic system. There are six known instances of disease-associated amyloid deposits in which the nature of the precursor protein for the amyloid protein is known: for primary amyloidosis, the source is an immunoglobulin light chain; for secondary amyloidosis, the precursor is amyloid A protein; for familial amyloid polyneuropathy and senile cardiac amyloidosis, prealbumin or a variant thereof; for medullary carcinoma of thyroid, a procalcitonin fragment; and for hereditary cerebral hemorrhage, gamma-trace fragment (See, e.g., Glenner, G. New England Journal of Medicine (1980) 302:1283; Sletton, K., et al., Biochem J (1981) 195:561; Benditt, et al., FEBS Lett (1971) 19:169; Sletton, K., et al., Eur J Biochem

SUBSTITUTE SHEET

(1974) 41:117; Sletton, K., et al., J Exp Med (1976) 143:993). The foregoing is a partial list and there are at least a number of additional references with regard to procalcitonin fragment as a precursor for the amyloid of the thyroid carcinoma. Alternatively, or additionally, such a precursor for β -amyloid core protein may be produced in the brain.

It has been described that a protein containing the β -amyloid core protein sequence within the framework of a larger protein exists (Kang, J., et al., Nature (1987) 325:733-736). This protein, which is a potential precursor in vivo to the β -amyloid core protein, was predicted from the sequence of a cDNA clone isolated from a human fetal brain tissue cDNA library and consists of 695 amino acid residues wherein the amino terminus of the β -amyloid core protein begins at position 597. By analogy to the above described series, it may be that such a precursor or a fragment thereof circulates in the serum at a level differentiable in Alzheimer's victims relative to unafflicted individuals. Alternatively or additionally, such differences may be detected in the cerebral spinal fluid.

Since the discovery of the novel precursor protein described in the present invention, others have characterized similar amyloid precursor proteins (Kitaguchi et al., Nature 331:530-532 (1988)) or a slightly larger, 770 amino acid amyloid precursor (Tanzi et al., Nature 331:528-530 (1988)), all of which contain an approximately 57 amino acid insert. This particular insert sequence is highly homologous to a number of Kunitz-type inhibitors which are specific for a number of serine proteases.

Summary of the Invention

Pharmaceutical compositions containing a 57 amino acid protease inhibitor and uses for those compositions are taught. Th protease inhibitor is

SUBSTITUTE SHEET

5 referred to as A4i which is associated with Alzheimer's disease. In addition to the A4i protease, other analogs are taught as are pharmaceutical compositions containing such analogs and their uses in treating a variety of abnormalities associated with Kunitz-type basic proteas inhibitors. For example, it has been found that pharmaceutical compositions containing A4i protease and analogs thereof inhibit plasmin and tryptase, and also inhibit pancreatic trypsin, alpha-chymotrypsin, tissue kallikrein and serum kallikrein. Certain diseases are associated with a general release of proteases such as trypsin, chymotrypsin and elastase into the circulatory system. Accordingly, pharmaceutical compositions containing A4i and analogs which inhibit the action of these proteases can be used in the management of such diseases.

20 An important object of the present invention is to provide an approved method for treating diseases associated with the release of proteases which involve administering to a patient suffering from such diseases a pharmaceutically effective amount of a protein (or analog thereof) having the following amino acid sequence:

25 GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle.

30 Yet another important object of the present invention is to provide pharmaceutical compositions comprised of pharmaceutically acceptable carriers and excipient materials in combination with the above-referred to protein.

35 Yet another important object of the present invention is to disclose and describe pharmaceutically acceptable compositions having fibrinolytic inhibitory activity which compositions are comprised of a

SUBSTITUTE SHEET

pharmaceutically acceptable carrier and excipient materials along with a fibrinolytically inhibitory effective amount of the above-referred to protein.

5 Another important object of the present invention is to provide pharmaceutical compositions and methods for using those compositions which are helpful in inactivating fibrin dissolution at a wound sight on a subject and thus promoting wound repair.

10 Another object of the present invention is to provide pharmaceutical compositions having thrombolytic activity which compositions are comprised of thrombolytically effective amounts of the above-referred to protein in combination with pharmaceutically acceptable excipient materials.

15 Important features of the present invention are that the pharmaceutical compositions of the invention are useful in inhibiting a wide range of biochemical reactions associated with diseases.

20 An advantage of the present invention is that the proteins used in the compositions of the invention are not toxic and do not cause undesirable side effects.

25 These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the structure, synthesis, formulation and usage as more fully set forth below, reference being made to the accompanying figures, DNA and amino acid sequences forming a part hereof.

30 Brief Description of the Drawings

Figure 1 shows the base sequence of a cDNA clone, designated λ APCP168i4, which encodes amino acids 1-751 of β -amyloid-related protein. The 168 bp insert, which distinguishes this clone from the Kang et al. sequence, is underlined.

35 Figure 2 shows a DNA sequence of a genomic clone encoding the first 18 amino acids of the β -amyloid

SUBSTITUTE SHEET

core protein as described by Masters et al. It also encodes, immediately preceding these amino acids, a methionine codon which could potentially be used as an initiating codon;

5 Figure 3 shows the base sequence of a cDNA clone, designated λ SM2W4, whose 3' end encodes the first four amino acids of β -amyloid core protein. It also encodes, immediately preceding these amino acids, a methionine codon as described above;

10 Figure 4 shows the base sequence of a cDNA clone, designated λ SM2W3, which encodes 97 amino acids; the first 26 of these correspond to the region of the β -amyloid core protein described by Masters et al., from Glu₃ through Ala₂₈;

15 Figure 5 shows the base sequence and corresponding amino acid sequence of a β -amyloid-related protein deduced from λ SM2W4 and λ SM2W3;

 Figure 6 shows the nucleotide and deduced amino acid sequence of the λ SM2W9 β -amyloid clone;

20 Figure 7 shows a comparison of the sequences of λ SM2W3 and λ SM2W9;

 Figure 8 shows the detection of mRNAs for λ APCP168i4 and the mRNA described by Kang et al. on a Northern blot produced using RNA's isolated from human brain and human cells in culture and hybridized to oligonucleotide probes which are specific for each species;

25 Figure 9 shows the construction scheme for a bacterial expression vector for the production of a β -amyloid-related protein in bacteria;

30 Figure 10 shows the construction scheme for a recombinant vaccinia virus expression vector for the expression of the protein encoded by λ APCP168i4;

 Figure 11 shows the construction scheme for a mammalian cell expression vector for the expression of the protein encoded by λ APCP168i4;

SUBSTITUTE SHEET

Figure 12 shows the construction of an expression vector for the production of the β -amyloid-related protein described in Figure 5, when the methionine encoded immediately upstream from the β -amyloid core protein sequence is used as an initiating methionine;

Figure 13 shows the relatedness of the peptide encoded by the λ APCP168i4 168 bp insert to a superfamily of proteins many of whose members exhibit inhibitory activity for basic proteases; and

Figure 14 shows the construction of a synthetic tryptophan operon promoter and operator regulatory sequence, and a restriction site map of plasmid pTRP233.

Figure 15 shows the results of a Western blot analysis of the CV-1 cells producing the 751 amino acid β -amyloid protein using β -amyloid specific polyclonal antisera. The control is the pSC11 vaccinia virus lacking the β -amyloid coding sequence.

Figure 16 is an illustration of the oligonucleotide sequences used to construct chimeric genes containing either the ompA signal sequence fused to the protease inhibitor sequence (FIG. 16A) or the phoA signal sequence fused to the protease inhibitor sequence (FIG. 16B). The asterisks indicate the individual oligonucleotides used for each construction.

Detailed Description of the Invention

Before the present pharmaceutical compositions containing protease inhibitors and analogs thereof and methods of using same are described, it is to be understood that this invention is not limited to the particular formulations or uses described as such formulations and uses may, of course, vary. It is also to be understood that the terminology used herein is for purposes of describing particular embodiments only, and

SUBSTITUTE SHEET

it not intended to be limiting since the scop of the present invention will be limited only by the appended claims.

It must be noted that as used in this specification and the appended claims, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a protease inhibitor" includes mixtures of such protease inhibitors, reference to "an analog of an inhibitor" includes mixtures of such analogs and reference to "the method of use" includes a plurality of such methods of the type known to those skilled in the art or which will become apparent to those skilled in the art upon reading this disclosure.

A. Definitions

As used herein, "β-amyloid core protein" means the protein described by Masters, C.L., et al., Proc Natl Acad Sci USA (1985) 82:4245-4249, herein referred to as "Masters, et al". This approximately 4 kD protein is defined at the amino terminus by sequence analysis as a mixture of four peptides with slightly different amino termini, the amino termini of the three smaller peptides being completely encoded by that of the largest. The first 28 amino acids of the longest form is Asp₁-Ala₂-Glu₃-Phe₄-Arg₅-His₆-Asp₇-Ser₈-Gly₉-Tyr₁₀-Glu₁₁-Val₁₂-His₁₃-His₁₄-Gln₁₅-Lys₁₆-Leu₁₇-Val₁₈-Phe₁₉-Phe₂₀-Ala₂₁-Glu₂₂-Asp₂₃-Val₂₄-Gly₂₅-Ser₂₆-Ser₂₇-Ala₂₈.

"β-amyloid-related protein or "β-amyloid-related peptide" are defined herein as those proteins containing within their sequence the β-amyloid core protein sequence defined above or fragments of such proteins which do not necessarily include the β-amyloid core protein sequence as defined above. As an example, this term is used to refer to the protein described by Kang, J., et al., Nature (1987) 325:733-736, herein

SUBSTITUTE SHEET

referred to as "Kang et al.", which contains the β -amyloid core protein within its structure at amino acid 597 of a 695 amino acid protein. As another example, it refers to the protein encoded by λ APCP168i4, shown in Figure 1, which, within its structure, contains the β -amyloid core protein at amino acid 653 of a 751 amino acid protein.

"Immunogenic β -amyloid core peptide" or "immunogenic β -amyloid-related peptide" refer to peptides whose amino acid sequences match those of some region of the β -amyloid core protein or β -amyloid-related protein, and which are capable of provoking an antibody response in an immunized animal.

"Genetic predisposition to Alzheimer's disease" refers to an identifiable genetic mutation or alteration found in the genomes of individual's with Alzheimer's disease, or those individuals destined to develop Alzheimer's disease, but not normal (nondiseased) individuals.

"A4i" as used herein refers to a polypeptide corresponding to the novel serine protease inhibitor encoded by the polynucleotide derived from the bacteriophage λ APCP168i4. The A4i polypeptide is not necessarily physically derived from the expression product of this bacteriophage, but may be generated in any manner, including peptide synthesis, recombinant DNA techniques or a combination thereof. "Corresponding" means homologous to or substantially equivalent to the designated sequence.

B. DNA Sequences

DNAs corresponding to β -amyloid core protein or β -amyloid-related protein sequences are useful as probes in diagnosis. Several DNAs containing sequences encoding portions of β -amyloid-related protein sequence, and β -amyloid core protein sequence with adjacent

SUBSTITUTE SHEET

noncoding segments are disclosed herein. These DNA sequences in whole or in part, are thus useful in diagnosis, either as intact probes, or as fragments.

5 In particular, the invention includes a DNA sequence which encodes a β -amyloid-related protein comprising the nucleotide sequence and corresponding, deduced amino acid sequence set forth in Figure 1. This DNA sequence encodes an approximately 82,610 dalton protein containing the β -amyloid-related core protein.

10 The present β -amyloid protein cDNA sequence, set forth in Figure 1, can be isolated from bacteriophage λ APCP168i4. This human fibroblast cDNA clone was obtained from a cDNA library prepared in λ gt10 using standard techniques from SV40-transformed
15 fibroblast (SV80) cells (Todaro, G.J., et al., Scienc (1966) 153:1252-1254). The λ gt10-SV80 library was screened with a mixture of labelled oligonucleotides. Two unique phage containing β -amyloid-related sequences were obtained; these β -amyloid-related sequences were
20 subcloned into a plasmid vector and sequencing analysis revealed a sequence co-linear with the sequence encoding the Kang et al. β -amyloid-related protein, except for the presence of a 168 basepair insert. The 168 basepair insert interrupts the codon for Val₂₈₉ of the Kang et
25 al. sequence, resulting in the loss of this amino acid from the λ APCP168i4 protein. The 168 basepair insert, together with the 3 basepairs gained from the interrupted Val₂₈₉ codon, encode 57 new amino acids, which are underlined in Figure 1. Downstream of this
30 insertion, at codon 653 of Figure 1, lies the amino-terminal aspartate of the β -amyloid core protein described by Masters et al. The λ APCP168i4 clone was deposited at ATCC on 1 July 1987 under the accession number 40347.

35 Particularly useful are those sequences which encode the 57 amino acid insert found in λ APCP168i4, as

SUBSTITUTE SHEET

well as sequences encoding the corresponding "junction" of the Kang et al. β -amyloid-related protein sequence.

For example, one preferred embodiment comprises DNA sequences encoding a β -amyloid-related protein having an amino acid sequence corresponding to residues 289 through 345 of the above-identified protein. Thus, this embodiment comprises a β -amyloid-related protein of the amino acid sequence:

10 Glu Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala
 10

Met Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys
 20

Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn
15 30 40

Phe Asp Thr Glu Glu Tyr Cys Met Ala Val Cys Gly Ser Ala
 50

Ile.

20 This particular peptide, including any
fragments thereof, distinguishes the present
8-amyloid-related protein from other reported forms.

In another preferred embodiment, the invention discloses a β -amyloid-related protein having the DNA sequence and deduced amino acid sequence corresponding to amino acid residues 284-Val₂₈₉-(V₂₈₉₋₃₄₅)-349 of the β -amyloid-related sequence set forth in Figure 1 (wherein V symbolizes a deletion of residues 289 through 345). An oligopeptide spanning this specific region would be useful to generate a protein specific diagnostic reagent to differentiate between the β -amyloid-related protein genetic variant described by Kang et al. and the β -amyloid-related protein of the present invention. Thus, this embodiment comprises a β -amyloid-related protein of the amino acid sequence:

SUBSTITUTE SHEET

Glu Glu Val Val Arg Val Pro Thr Thr Ala

A smaller peptide contained within the sequence of this peptide might also be used.

5 Oligonucleotides specific for the 168 basepair insert and for the junctions of this region of the β -amyloid-related protein described by Kang et al. can be synthesized and used to compare the levels of mRNA expression of these two distinct proteins. As an
10 example, oligonucleotides specific for the 168 basepair insert, designated oligo #2734:

10 20 30 40 50
(CGCCGTAAAA GAATGGGGCA CACTTCCCTT CAGTCACATC AAAGTACCAG
15 60
CGGGAGATCA)

and for the "junction" region, designated oligo #2733:

10 20 30
20 (CTGCTGTTGT AGGAACTCGA ACCACCTCTT)

were synthesized using phosphoramidite chemistry on an Applied Biosystems DNA synthesizer.

25 The "junction" oligo is complementary to 15 basepairs on either side of the insert and is used to distinguish between the published β -amyloid-related protein sequences and the λ APCP168i4 sequences by specific hybridization conditions known in the art under which a 15 basepair perfect match is unstable, while a
30 30 basepair perfect match is stable. These oligonucleotides are used to screen cDNA libraries or mRNA from various sources as an assay for measuring the level of expression of a specific sequence.

35 Another example, described below, is a genomic sequence encoding the first 18 amino acids (19 if Met is included) of the β -amyloid protein sequence characteristic of Alzheimer's disease in neuritic

SUBSTITUTE SHEET

plaques. The clone was obtained in λ Charon 4A from the genomic library described by Lawn, R.M., et al., Cell (1978) 15:1157-1174 and has been partially sequenced, as shown in Figure 2. As seen, the sequenced portion of the genomic clone includes a 57 base pair segment which encodes the amino acids 1-18 of the previously reported β -amyloid core protein and a methionine immediately preceding. Downstream of the amino acid 18 codon, the genomic sequence diverges in codon sequence from that expected from the reported amino acid sequence of β -amyloid core protein. By reference to the protein encoded by the sequence of Figure 4, and by inspection of the sequences flanking this region using knowledge known in the art, this divergence is likely to be an intron sequence. This clone, designated λ SM2, was deposited at ATCC on 13 November 1986.

A HindIII/RsaI probe derived from the genomic clone (see Figure 2) was used as a probe to isolate, according to standard procedures, cDNA fragments from a cDNA library constructed in λ gt10 from temporal and parietal cortical tissue of a normal human brain (the individual was a 55 year old man who died of myocardial infarction). The three cDNA clones which were isolated were sequenced conventionally, and matched with amino acid sequences in each of the three possible reading frames to identify regions coding for β -amyloid-related proteins. One of the clones, designated λ SM2W4, contains a 3'-end terminal sequence which encodes the Asp Ala Glu Phe amino acids at the 5'-end of β -amyloid-core protein, as seen in Figure 3, which shows the complete base sequence of the clone. The Asp1 codon is immediately preceded by a methionine codon. A second clone, designated λ SM2W3, contains a 5' region segment which has a 6 bp overlap with the 3' end of the λ SM2W4 clone (an EcoRI restriction site), encoding amino acids 3 and 4 of the β -amyloid core protein, and an additional

SUBSTITUTE SHEET

95 codons which encode the remainder of a
β-amyloid-related protein. The DNA sequence for the 100
amino acid protein (including Met) encoded in λSM2W4 and
λSM2W3 is shown in Figure 5. It is, of course,
5 understood that the methionine is probably processed in
vivo, and that the β-amyloid-related protein represented
in this figure may thus be a 99 amino acid sequence.

A third cDNA clone encodes a portion of a
β-amyloid-related protein which differs from λSM2W3 in
10 the region shown by 15 nucleotide differences and 4
amino acid differences in the region of amino acids 3-44
of Figure 5. The DNA sequence and deduced amino acid
sequence for this clone, designated λSM2W9 are given in
Figure 6. A comparison with λSM2W3 is given in
15 Figure 7.

C. Protein Production

The cDNA clones described herein permit
construction of coding sequences which may be expressed
20 to obtain a complete β-amyloid-related protein, an 100
amino acid β-amyloid-related protein containing the
amino-terminal sequences reported for β-amyloid core
protein, and other desired proteins. These sequences
can be inserted in a suitable expression vector for
25 production of protein. Details of the method of
constructing a DNA subsequence of Figure 1 and insertion
of this sequence into a bacterial expression vector is
provided in Example 2.

Briefly, an E. coli expression vector,
30 designated pAPCP118-3, was constructed for the
expression of a fusion protein consisting of amino acid
residues 655 to 751 set forth in Figure 1. The
construction of pAPCP118-3 was accomplished by joining
the following three fragments: (1) a plasmid backbone
35 (consisting of pBR322 replication functions, an
ampicillin resistance gene, the tryptophan promoter and

SUBSTITUTE SHEET

operator, a ribosome binding site, DNA encoding the seven amino terminal codons of the β -galactosidase structural gene followed by six threonine residues, and transcription termination signals); (2) an EcoRI-HaeII
5 fragment encoding amino acid residues 655-728 of the Figure 1 sequence; and (3) a synthetic fragment encoding amino acid residues 729-751 of the Figure 1 sequence, followed by a stop codon.

The resulting vector was used to transform E. coli W3110 and expression of the fusion protein was
10 induced by reducing the tryptophan concentration followed by the addition of 3- β -indoleacrylic acid. The resulting protein can be purified using conventional purification techniques and the resulting purified
15 material is available for use in the production of antibodies for diagnostic assays.

The complete coding sequence of the β -amyloid-related protein set forth in Figure 1 was subcloned in two fragments from the deposited λ APCP168i4 clone and
20 inserted into pSC11, a vaccinia virus expression vector. The construction of the resulting vector, pFL4T4BV, is illustrated in Figure 10. Briefly, an approximately 1.06 kilobase (kb) EcoRI fragment, spanning amino acid residues 655-751 of the protein illustrated in Figure 1,
25 was cloned into EcoRI-digested plasmid pGEM-3TM (available from Promega Biotec) to create an intermediate vector designated p4BI. Subsequently p4BI was digested with HindIII to remove much of the 3'-noncoding sequence of the β -amyloid-related sequence.
30 The resulting vector p4BARI was digested with EcoRI and treated with calf intestinal alkaline phosphatase prior to ligation to the 2088 bp EcoRI fragment derived from λ APCP168i4 to form p4T4B. This plasmid was digested with SmaI and XmnI to generate a 2678 bp fragment
35 spanning the complete protein encoding sequence set forth in Figure 1.

SUBSTITUTE SHEET

5 The gene encoded by this SmaI-XmnI fragment
was inserted into a well-known vaccinia viral vector,
pSC11, for subsequent expression of the
8-amyloid-related protein in CV-1 monkey kidney cells
using a eucaryotic transient expression system as
described by Cochran, M.A., et al., Proc Natl Acad Sci
USA (1985) 82:19-23. More commonly, this vector is used
for in vivo protein and antibody production in animals
after its sequences have been inserted into the vaccinia
10 virus genome (see "Antibody Production" section below).

Similarly, mammalian vectors can be utilized
for expression of the 8-amyloid core protein or
8-amyloid-related proteins described herein. For
example, plasmid pHGH-SV (10) (a plasmid described in
15 EPA 217,822, published 15 April 1987, and incorporated
herein by reference) contains a pUC8 plasmid backbone,
hMT-IIa gene promoter and regulator elements, SV-40 DNA
promoter and enhancer elements, and the coding portions
of the hGH gene and 3' regulatory sequences. This
20 plasmid can be digested with BamHI and SmaI and treated
with BamHI linkers to delete the human growth hormone
protein encoding sequence and leaving the 3'-noncoding
sequences and regulatory elements attached to the
plasmid backbone. This approximately 5100 base pair DNA
25 piece is gel purified and ligated to BamHI linkers.
Digestion with BamHI, repurification of the DNA fragment
and subsequent ligation result in a plasmid designated
pMTSV40 polyA Bam which contains the structural and
regulatory elements comprising a mammalian cell
30 expression vector. After BamHI digestion of pMTSV40
polyA BamHI and repair in the presence of DNA polymerase
I and all four dNTPs, this vector is available for
insertion of the ~ 2678 bp SmaI-XmnI restriction
fragment of plasmid p4T4B. The resulting vector can
35 then be used for efficient protein expression in CHO
cells as described in Example 4.

SUBSTITUTE SHEET

In addition, the sequence information from the λ SM2W4 clone, illustrated in Figure 3, combined with the sequences present in the λ SM2W3 clone, may be used to construct a mammalian cell expression vector encoding the protein described in Figure 5.

The secreted protease inhibitor may be recovered in a biologically active, refolded and substantially pure form from the bacterial broth using a solid support affinity matrix, such as, for example, Sepharose beads, to which a serine protease with high affinity for the inhibitor activity is bound. Enzymes available for this use include, for example, the human serine proteases trypsin and chymotrypsin. Once the protease inhibitor is captured on the beads, the protein may be eluted using acid conditions, such as a low pH environment in the range of about 1.0 to about 5.0, preferably 1.25. The eluted protein may be substantially purified, i.e., recovered at least 70%, preferably 80%, more preferably 90%, most preferably at least 95%, as measured by high performance liquid chromatography (HPLC) (e.g., a C4 column using a 60% acetonitrile 0.1%/trifluoroacetic acid elution gradient).

D. Antibody Preparation

Antibodies specific against β -amyloid core protein and β -amyloid-related proteins are prepared by known procedures. As an example using synthetic peptides, typically the protein sequence is analysed for regions of at least about 10 amino acids long which have predominantly polar and/or charged amino acid residues to identify favorable immunogenic regions.

As another example, the DNA sequence shown in Figure 1 can be used to design oligopeptides which are specific to the inserted sequence in λ APCP168i4, as well as the corresponding junction of this insert to the β -amyloid-related protein described by Kang et al. For

SUBSTITUTE SHEET

example, an oligopeptide spanning the inserted junction such as Glu-Glu-Val-Val-Arg-Val-Pro-Thr-Thr-Ala may be used to immunize animals to produce a specific antisera against this region of the protein described by Kang et al. Inspection of the Kang et al. sequence in the absence of knowledge of the λ APCP168i4 sequence would not provide the information necessary to identify this peptide as a valuable reagent by any method known in the art. As another example, oligopeptides designed to represent sequences present in the 168 basepair insert region could be used in a similar manner to generate antisera against this unique region of the APCP168i4 protein. Thus, the regions identified as favorable for immunogenicity are synthesized by conventional peptide synthetic methods, and coupled covalently to a suitable carrier protein, such as keyhole limpet hemocyanin. Antibodies are raised against the peptide/protein conjugate in rabbits or the like by conventional methods. The presence of antibody in immunized animals is detected by standard methods, such as immunoreactivity to the immunizing synthetic peptide affixed to a microtiter plate, followed by ELISA.

Another method of antibody production uses the bacterially produced β -amyloid-related fusion protein of Example 2 as the immunogen. The immunogenicity of this protein is shown by the immunoreactivity of the antisera to the bacterially produced fusion protein.

Yet another method of antibody production relies on the inoculation of the host animal with a live recombinant vaccinia virus encoding β -amyloid-related protein, such recombinant viruses being generated by established techniques involving recombination between wild-type vaccinia virus and the vectors derived from pSC11, such as pFL4T4BV, described herein. These antibodies can then be used in the diagnostic assays described below.

SUBSTITUTE SHEET

A panel of antibodies which are specific against peptides derived from different regions of the β -amyloid-related protein, such as the A4i peptide, are further analysed for immunoreactivity of β -amyloid-related proteins present in the serum or cerebral spinal fluid of patients with Alzheimer's disease, to identify antibodies suitable for a diagnostic assay for Alzheimer's disease, as discussed below.

E. Diagnostic and Prognostic Methods

The DNA sequences described in Figures 3, 4, and 6 for β -amyloid-related protein are primarily derived from an apparently normal advanced-age male showing no signs of Alzheimer's disease at the time of death. The λ APCP168i4 sequence described in Figure 1 for another β -amyloid-related protein is derived from cultured fibroblast cells. These sequences provide a standard for identifying mutations in genomic sequences which are found in individuals with Alzheimer's disease, and which are therefore likely to be associated with a predisposition to the disease.

1. Prognostic Methods. Assays are used to determine an individual's genetic predisposition to Alzheimer's disease. These tests use the DNA sequences of the present invention in a comparative study with samples of the patient's DNA to define polymorphisms in the region of the chromosome containing the β -amyloid gene. Alternatively or concurrently, the DNA sequences of the present invention can be used in nucleic acid hybridization analysis to define alterations, which alterations are meant to include additions, deletions, mutations or substitutions, in the DNA or RNA encoding β -amyloid-related proteins.

Alterations in the β -amyloid-related protein sequences which correlate with Alzheimer's disease can

SUBSTITUTE SHEET

be assayed by a differential probe binding method. Under appropriate hybridization conditions, known in the art, the oligonucleotide probes will bind to completely complementary sequences, but not to closely related but altered sequences.

In one assay method, nucleic acid samples prepared from the test subject are hybridized with each probe, under the defined hybridization conditions, and examined for binding to specific oligonucleotides.

Alterations, and thus predisposition to Alzheimer disease, are confirmed by binding one probe, but not to the other probe. The probe-binding method, as it has been applied to other genetic diseases, is described in Conner, B.J., et al., Proc Nat Acad Sci (USA) (1983) 80:278-282.

Alternatively, probes derived from the genomic or cDNA sequences described above may be used to identify restriction fragment length polymorphisms which are associated with a genetic predisposition to Alzheimer's disease. Initially the probes are used to identify restriction site fragment lengths from both normal and diseased genomic digest samples. Changes in restriction fragment lengths which correlate with Alzheimer's disease are then applied to genetic screening, by standard methods. That is, test subject genomic material is digested with the restriction enzyme(s) of interest, and the fragment pattern on Southern blotting is determined with the labeled probe.

2. Diagnostic Methods. In various other clinical amyloidoses, the amyloidogenic peptides are variants of normally expressed gene products. These peptides have been altered either by aberrant proteolytic processing or by genetic lesions yielding an alteration in the primary amino acid sequences. There are known amyloidosis, such as Familial Amyloid Polyneuropathy (FAP), in which a mixture of the normal

SUBSTITUTE SHEET

precursor and the amyloidogenic variant coexist within the circulation. An aberrant tissue-distribution for the expression of the aberrant gene product, or some other alteration in its level of expression, its
5 sequence, or its processing in Alzheimer's disease could have significance in terms of the etiology of amyloid deposition.

A first diagnostic test which utilizes the materials of the invention is a direct antibody assay
10 for the increase or decrease of β -amyloid core protein or β -amyloid-related proteins in Alzheimer's individuals relative to normal individuals. In this method, antibodies obtained as described above are screened for specific immunoreactivity with proteins from individuals
15 known to have Alzheimer's disease. The presence of immunoreactive serum proteins is determined by standard immunoassay techniques, such as solid-phase ELISA techniques.

The body sample which is assayed for the
20 presence of β -amyloid core protein or β -amyloid-related protein is, for example, serum or cerebral spinal fluid. For instance, in hereditary cerebral hemorrhage with amyloidosis, a disorder wherein the amyloid is generated from the gamma-trace precursor, the precursor can be
25 detected in cerebrospinal fluid using an immunoassay. The levels of the precursor are reduced in the patients having the disease, leading to the conclusion that it is used up during the formation of the deposits. The precursor is made in the brain, and hence the
30 cerebrospinal fluid is the appropriate sample.

In another diagnostic test, DNA encoding β -amyloid-related protein is directly useful as a probe to detect an increase or decrease in synthesis of mRNAs encoding β -amyloid-related proteins in the appropriate
35 target cells by virtue of its ability to hybridize to

SUBSTITUTE SHEET

th appropriate mRNA. An example showing the utility of this method is given in Example 5 below.

5 A third diagnostic assay permits the detection of antibodies against the amyloid protein in patient's serum using such standard ELISA techniques wherein th purified recombinant amyloid protein or synthetic peptide is bound to the solid support.

F. Therapeutic Methods.

10. The invention also provides for improved therapeutic treatments for Alzheimer's disease. One therapeutic treatment is suggested by the sequence of the A4i protein encoded by the 168 bp insert in λ APCP168i4.

15 By comparing the degree of relatedness of one protein to another, the amino acid sequence of the A4i protein was found to be homologous to a family of proteins known as Kunitz-type basic protease inhibitors. The level of relatedness of the insert protein segment to three members of the Kunitz family is shown in Figure 13, where the symbol (:) indicates an identity between the two sequences compared and the symbol (.) indicates the substitution of an amino acid with similar chemical properties.

25 The comparison showed that the insert sequence depicted by the one-letter amino acid code as EVCS ... GSAI is related to a high degree over its entire length to all members of the Kunitz family (only three are shown as an example). The three comparisons shown in figures 13-1 and 13-2 are to: (1) a human trypsin inhibitor, a secreted plasma protein which inhibits trypsin, plasmin and lysosomal granulocytic elastase (Wachter, E., and Hochstrasser, K. Hoppe-Seyler's Z
30 Physiol Chem (1981) 362:1351-1355; Morii, M., and Travis, J. Biol Chem Hoppe-Seyler (1985) 366:19-21; (2)
35 a bovine trypsin inhibitor which inhibits trypsin,

SUBSTITUTE SHEET

chymotrypsin, elastases and plasmin (Hochstrasser, K. and Wachter, E., Hoppe-Seyler's Z Physiol Chem (1983) 364:1679-1687; Hochstrasser, K., et al., Hoppe-Seyler's Z Physiol Chem (1983) 364:1689-1696; and (3) a bovine serum basic protease inhibitor (and its precursor) which inhibits trypsin, kallikrein, chymotrypsin, and plasmin (Anderson, S. and Kingston, I.B. Proc Nat Acad Sci (USA) (1983) 80:6838-6842. Based on this level of relatedness to the A4i protein sequence, one interpretation is that this region of the λ APCP168i4 protein functions as a protease inhibitor in vivo.

Alzheimer's disease has been associated with the formation of amyloid plaques. Further, amyloid is formed as a result of the proteolysis of the β -amyloid precursor protein. The A4i protein is believed to prevent the cleavage of the β -amyloid precursor thus preventing the formation of the β -amyloid protein. Reducing the amount of β -amyloid formed may reduce plaque formation.

The present invention is not bound by the above interpretation. An alternative mechanism of action for the inhibitor which would give the same result (reduced plaque formation) via a different mechanism can be provided. The A4i protein could act as a protease inhibitor and inhibit a protease which degrades the plaque. Administration of an antagonist, for example a peptide or a specific antibody (either monoclonal or polyclonal) that is specific for the inhibitor to block the interaction of the inhibitor to the protease would allow for the plaque to be degraded and as such be therapeutically useful.

The A4i inhibitor or other inhibitors, peptidic or non-peptidic, could be used to treat or prevent Alzheimer's disease by a mechanism such as preventing the formation of neuritic plaques or allowing the plaque formed to be readily degraded. One method of

SUBSTITUTE SHEET

administration might involve nasal delivery of such a peptide which would provide for transmucosal delivery and thus avoid the GI tract and the destruction of the peptide therein. Nasal delivery systems could be produced by formulating a solution containing the protease inhibitor peptide with one or more excipients and an effective amount of an adjuvant, such as the fusidic acid derivatives or a polyoxyethylene ether at a concentration in the range of about 0.1-10% (w/w). It should be pointed out that the effectiveness of A4i may be dependent on or be influenced by the ability to deliver the inhibitor locally to the brain. If delivery to the brain is needed, special considerations related to the blood-brain barrier must be dealt with because exchange of materials across the cerebral vessels is different from that in other capillary beds. Attaching the A4i to delivery vehicles known to enhance delivery of material across the blood-brain barrier might be useful. Stabilizers, preservatives and other components normally present in nasal delivery systems could optionally be added. The amount of peptide would vary, depending on its efficacy and bioavailability, but could range from about 0.1-25% (w/w).

The nasal systems could be administered by spraying from 10-100 μ l of the solution into each side of the nose from 1-4 times a day. However, it should be noted that dosing could also be more or less frequent and would be adjusted during use depending upon the needs of the particular patient. Other modes of delivery include a solution of inhibitor in a pharmaceutically acceptable excipient where the inhibitor is 0.1-25% (w/w) and where the inhibitor is administered by injection into the cerebrospinal fluid, or directly onto the brain. A more localized administration to the central nervous system is believed to be preferred. However, if plaques accumulate

SUBSTITUTE SHEET

systemically, the inhibitor may be administered intravenously. Further, if the inhibitor is non-peptidic, oral dosing may be possible.

5 The A4i protein and analogs thereof have applicability outside the treatment of Alzheimer's disease as indicated by their specificity profile. For example, it has been found that the A4i of the present invention strongly inhibits plasmin and tryptase, and also inhibits pancreatic trypsin, α -chymotrypsin, tissue
10 kallikrein and serum kallikrein. The inhibitor did not inhibit chymase, pancreatic elastase, α -thrombin, urokinase, papain or cathepsin B. In acute pancreatitis, there is a general release of digestive proteases such as trypsin, chymotrypsin and elastase, from the
15 pancreas into the circulation. It would be useful in the clinical management of pancreatitis to administer A4i with one or more protease inhibitors systemically to inactivate these proteases.

 It is pointed out that aprotinin, a
20 bovine-derived protease inhibitor sharing approximately 50% amino acid homology with the present A4i inhibitor, has been found to have clinical utility in animal models (H. Fritz and G. Wunderer, Drug Res 33(1), No. 4 (1983) pp. 479-494). The bovine inhibitor, sold under the
25 Trademark Trasylol, is marketed in Europe for use in connection with acute pancreatitis. One advantage of the A4i over a bovine inhibitor is that A4i is naturally present in low levels in the circulation in the form of its larger precursor. Accordingly, A4i would not
30 generate an allergic or immune reaction as might be expected with aprotinin or other inhibitors of non-human origin.

 The significant affinity of A4i for the plasma proteases plasmin and tryptase makes possible the in
35 vivo regulation of specific coagulation factors. Plasmin is important in lysing fibrin clots (i.e.

SUBSTITUTE SHEET

fibrinolysis) whereas tryptase is involved in clot formation. Administration of effective dosages of the A4i would aid in regulating clot formation and clot dissolution.

5 Fibrin glue used in wound healing contains aprotinin which could be replaced with A4i. Accordingly, A4i polypeptide may be employed to augment tissue repair necessary for wound healing. The strong affinity of A4i for plasmin is believed to interfere with plasmin's fibrinolytic activity. This activity is particularly effective when A4i is used in an adhesion fibrin ("fibrin glue") for adapting tissues and sealing bleeding areas with fibrin, preventing its dissolution before tissue repair has set in such as with surgical lacerations.

10 The strong affinity of the A4i polypeptide for tryptase makes the inhibitor directly useful in anticoagulant treatments by inhibiting prothrombin activation in vivo. The dissociation constant of A4i is $K_i = 2.2 \times 10^{-10}$ which is similar to that reported for mast cell trypstatin on tryptase (Kido et al., J Biol Chem 263:18104-18107 (1988)), which has been shown to effectively inhibit the amidase activities of mast cell tryptase. Thus, A4i can be employed as an exogenously administered thrombolytic agent.

25 Generally, an inhibitor composition is applied to the site of the wound by soaking a nonadhesive surgical dressing in the composition or alternatively, by incorporating the composition into a slow-release matrix and applying it at the site of the wound.

30 A pharmaceutical composition may be made from the purified inhibitor in a conventional way, with or without the use of additives such as sodium chloride, glucose, mannitol, albumin, and the like. The compositions will mostly be suitable for parenteral

SUBSTITUTE SHEET

administration, including intravenous or intraarterial injection or infusion.

5 The resulting composition may be administered to patients in a suitable dose and may be used prophylactically to prevent acute and chronic thromboembolic occlusions of different vascular beds, such as encountered in deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, arterial occlusion, extracorporeal circulation and arteriovenous shunts. For this purpose it would be necessary to insure that the A4i acts specifically on tryptase and would not be a significant inhibitor of plasmin.

10 The involvement of plasmin in the liberation of cancer cells from cancerous tissue has been observed. Inhibition of plasmin and other proteases with A4i may significantly reduce or prevent tumor growth.

15 Proteases found in normal tissues may be produced in excess and be involved in tissue inflammation and damage. Inhibition of protease release might lead to reduced tissue damage and inflammation. Allergic reactions causing release of protease would also be amenable to treatment by protease inhibition.

20 Other forms of the present A4i protein are provided herein. These other forms are analogs of A4i, which is the 57 amino acid protease inhibitor. These analogs contain at least one amino acid substitution which is effective to yield an inhibitor having altered protease specificity. The residue termed P₁ is known to play a major role in defining the specificity of a protease inhibitor. In the mature secreted inhibitor of the invention, this P₁ residue is Arg₁₃ which is expected to direct this inhibitor to enzymes having trypsin-like activities.

25 By analogy to aprotinin, wherein it has been shown that modification to its P₁ residue has modified the protease activity of the inhibitor (see Gebhard, W.,

SUBSTITUTE SHEET

et al., in Proteinase Inhibitors, eds. Barrett and
Salvesin, Amsterdam, N.Y., Oxford: Elsevier 1986),
modification via site-specific mutagenesis of the
present inhibitor produces similar results. For
5 enhanced inhibition of enzymes having chymotrypsin
activity, Arg₁₃ of the present inhibitor is substituted
with aromatic amino acids such as, for example, Phe, Tyr
and Trp; whereas to produce an inhibitor having enhanced
ability to inhibit enzymes possessing human elastase
10 activity, the Arg₁₃ residue is substituted with neutral
hydrophobic amino acids such as, for example, Leu, Met
and Val.

The analogs of the present protease inhibitors
are constructed from oligonucleotides containing the
15 specific codons encoding the desired amino acid at this
location, using site-specific mutagenesis techniques as
are known in the art. The desired activities of the
analogs thus constructed are assayed using the
appropriate enzyme, for example, either trypsin,
20 chymotrypsin or elastase as the standard in one of the
respective assays using, for example, the trypsin or
chymotrypsin assays described in Tan, N.H. Biochem
(1977) 16:1531-1541 and the elastase assays in Barrett,
A.J. (1981) in Methods in Enzymology vol. 80, L. Lorand
25 ed., Academic Press, New York. The activity of the
analogs may be compared with that of the natural
protease inhibitor of the invention. The kinetics of
inhibition (K_i) of the natural protease inhibitor for
trypsin ($K_i=3 \times 10^{-9}M$) and chymotrypsin ($8.5 \times 10^{-9}M$)
30 are in the nanomolar range and therefore, quite
specific.

G. Methods and Materials

Most of the techniques which are used to
35 transform cells, construct vectors, extract messenger
RNA, prepare cDNA libraries, and the like are widely

SUBSTITUTE SHEET

practiced in the art, and most practitioners are familiar with the standard resource materials which describe specific conditions and procedures. However, for convenience, the following paragraphs may serve as a guideline.

Hosts and Control Sequences

Both procaryotic and eucaryotic systems may be used to express the β -amyloid core and β -amyloid-related sequences; procaryotic hosts are, of course, the most convenient for cloning procedures. Procaryotes most frequently are represented by various strains of E. coli; however, other microbial strains may also be used. E. coli strains may secrete the β -amyloid core and β -amyloid-related proteins to the periplasm when the genes encoding these proteins are fused to appropriate signal peptides, and certain E. coli strains, for example, a lipoprotein mutant strain such as JE5505 (Kanamari, T. Gene (1988) 66:295-300), will excrete the chimeric proteins directly to the culture medium.

Plasmid vectors which contain replication sites, selectable markers and control sequences derived from a species compatible with the host are used; for example, E. coli is typically transformed using derivatives of pBR322, a plasmid derived from an E. coli species by Bolivar et al., Gene (1977) 2:95. pBR322 contains genes for ampicillin and tetracycline resistance, and thus provides multiple selectable markers which can be either retained or destroyed in constructing the desired vector. Commonly used procaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the β -lactamase (penicillinase) and lactose (lac) promoter systems (Chang et al., Nature (1977) 198:1056)

SUBSTITUTE SHEET

and the tryptophan (trp) promoter system (Goeddel et al. Nucleic Acids Res (1980) 8:4057) and the lambda-derived P_L promoter and N-gene ribosome binding site (Shimatake et al., Nature (1981) 292:128).

5 Other procaryotic control sequences include signal sequences which direct secretion of a protein to the periplasm. Commonly used bacterial signal peptides include the ompA (Kikuchi et al., Nucleic Acids Res (1981) 9:5671-5678) and phoA (Beck and Bremer, Nucleic
10 Acids Res (1980) 8:3011-3024) signal peptides which can be fused to the protease inhibitor sequence of the invention.

In addition to bacteria, eucaryotic microbes, such as yeast, may also be used as hosts. Laboratory
15 strains of Saccharomyces cerevisiae, Baker's yeast, are most used although a number of other strains or species are commonly available. Vectors employing, for example, the 2 μ origin of replication of Broach, J. R., Meth Enz (1983) 101:307, or other yeast compatible origins of
20 replication (see, for example, Stinchcomb et al., Nature (1979) 282:39, Tschumper, G., et al., Gene (1980) 10:157 and Clarke, L., et al., Meth Enz (1983) 101:300) may be used. Control sequences for yeast vectors include
25 promoters for the synthesis of glycolytic enzymes (Hess et al., J Adv Enzyme Reg (1968) 7:149; Holland et al., Biochemistry (1978) 17:4900). Additional promoters known in the art include the promoter for
3-phosphoglycerate kinase (Hitzeman et al., J Biol Chem (1980) 255:2073). Other promoters, which have the
30 additional advantage of transcription controlled by growth conditions and/or genetic background are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes
associated with nitrogen metabolism, the alpha factor
35 system and enzymes responsible for maltose and galactose utilization. It is also believed terminator sequences

SUBSTITUTE SHEET

are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes.

It is also, of course, possible to express genes encoding polypeptides in eucaryotic host cell cultures derived from multicellular organisms. See, for example, Axel et al., U.S. Patent No. 4,399,216. These systems have the additional advantage of the ability to splice out introns and thus can be used directly to express genomic fragments. Useful host cell lines include VERO and HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers et al., Nature (1978) 273:113), or other viral promoters such as those derived from polyoma, Adenovirus 2, bovine papilloma virus, or avian sarcoma viruses. The controllable promoter, hMTII (Karin, M., et al., Nature (1982) 299:797-802) may also be used. General aspects of mammalian cell host system transformations have been described by Axel (supra). It now appears, also that "enhancer" regions are important in optimizing expression; these are, generally, sequences found upstream or downstream of the promoter region in noncoding DNA regions. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes.

Transformations

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, S.N., Proc Natl Acad Sci (USA) (1972) 69:2110, or the RbCl₂

SUBSTITUTE SHEET

method described in Maniatis et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Press, p. 254 and Hanahan, D., J Mol Biol (1983) 166:557-580 may be used for procaryotes or other cells which contain substantial cell wall barriers. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology (1978) 52:546, optionally as modified by Wigler, M., et al., Cell (1979) 16:777-785 may be used.

Transformations into yeast may be carried out according to the method of Beggs, J.D., Nature (1978) 275:104-109 or of Hinnen, A., et al., Proc Natl Acad Sci (USA) (1978) 75:1929.

Vector Construction

Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques which are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired.

The DNA sequences which form the vectors are available from a number of sources. Backbone vectors and control systems are generally found on available "host" vectors which are used for the bulk of the sequences in construction. For the pertinent coding sequence, initial construction may be, and usually is, a matter of retrieving the appropriate sequences from cDNA or genomic DNA libraries. However, once the sequence is disclosed it is possible to synthesize the entire gene sequence in vitro starting from the individual nucleotide derivatives. The entire gene sequence for genes of sizeable length, e.g., 500-1000 bp may be prepared by synthesizing individual overlapping complementary oligonucleotides and filling in single stranded nonoverlapping portions using DNA polymerase in

SUBSTITUTE SHEET

the presence of the deoxyribonucleotide triphosphates. This approach has been used successfully in the construction of several genes of known sequence. See, for example, Edg, M. D., Nature (1981) 292:756; Nambair, K. P., et al., Science (1984) 223:1299; Jay, Ernest, J Biol Chem (1984) 259:6311.

Synthetic oligonucleotides are prepared by either the phosphotriester method as described by Edge, et al., Nature (supra) and Duckworth et al., Nucleic Acids Res (1981) 9:1691 or the phosphoramidite method as described by Beaucage, S.L., and Caruthers, M.H., Tet Letts (1981) 22:1859 and Matteucci, M.D., and Caruthers, M.H., J Am Chem Soc (1981) 103:3185 and can be prepared using commercially available automated oligonucleotide synthesizers. Kinasing of single strands prior to annealing or for labeling is achieved using an excess, e.g., approximately 10 units of polynucleotide kinase to 1 nmole substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl₂, 5 mM dithiothreitol, 1-2 mM ATP, 1.7 pmoles γ 32P-ATP (2.9 mCi/mmole), 0.1 mM spermidine, 0.1 mM EDTA.

Once the components of the desired vectors are thus available, they can be excised and ligated using standard restriction and ligation procedures.

Site specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 μ g of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 μ l of buffer solution; in the examples herein, typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about

SUBSTITUTE SHEET

37°C are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology (1980) 65:499-560.

Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20 to 25°C in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl₂, 6 mM DTT and 0.1-1.0 mM dNTPs. The Klenow fragment fills in at 5' single-stranded overhangs but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the, or selected, dNTPs within the limitations dictated by the nature of the overhang. After treatment with Klenow, the mixture is extracted with phenol/chloroform and ethanol precipitated. Treatment under appropriate conditions with S1 nuclease or BAL-31 results in hydrolysis of any single-stranded portion.

Ligations are performed in 15-50 µl volumes under the following standard conditions and temperatures: for example, 20 mM Tris-HCl pH 7.5, 10 mM MgCl₂, 10 mM DTT, 33 µg/ml BSA, 10 mM-50 mM NaCl, and either 40 µM ATP, 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for "sticky end" ligation) or 1 mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 14°C (for "blunt end" ligation). Intermolecular "sticky end" ligations are usually performed at 33-100 µg/ml total DNA

SUBSTITUTE SHEET

concentrations (5-100 nM total end concentration). Intermolecular blunt end ligations are performed at 1 μ M total ends concentration.

5 In vector construction employing "vector fragments", the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase (CIP) in order to remove the 5' phosphate and prevent self-ligation of the vector. Digestions are conducted at pH 8 in approximately 10 mM
10 Tris-HCl, 1 mM EDTA using about 1 unit of BAP or CIP per μ g of vector at 60° for about one hour. In order to recover the nucleic acid fragments, the preparation is extracted with phenol/chloroform and ethanol precipitated. Alternatively, religation can be
15 prevented in vectors which have been double digested by additional restriction enzyme digestion and separation of the unwanted fragments.

For portions of vectors derived from cDNA or genomic DNA which require sequence modifications, site
20 specific primer directed mutagenesis may be used (Zoller, M.J., and Smith, M. Nucleic Acids Res (1982) 10:6487-6500 and Adelman, J.P., et al., DNA (1983) 2:183-193). This is conducted using a primer synthetic oligonucleotide complementary to a single stranded phage
25 DNA to be mutagenized except for limited mismatching, representing the desired mutation. Briefly, the synthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the phage, and the resulting partially or fully double-stranded DNA is
30 transformed into a phage-supporting host bacterium. Cultures of the transformed bacteria are plated in top agar, permitting plaque formation from single cells which harbor the phage.

35 Theoretically, 50% of the new plaques will contain the phage having, as a single strand, the mutated form; 50% will have the original sequence. The

SUBSTITUTE SHEET

5 resulting plaques are washed after hybridization with kinased synthetic primer at a wash temperature which permits binding of an exact match, but at which the mismatches with the original strand are sufficient to prevent binding. Plaques which hybridize with the probe are then picked, cultured, and the DNA recovered.

Verification of Construction

10 In the constructions set forth below, correct ligations for plasmid construction are confirmed by first transforming E. coli strain MC1061 obtained from Dr. M. Casadaban (Casadaban, M., et al., J Mol Biol (1980) 138:179-207) or other suitable host with the ligation mixture. Successful transformants are selected
15 by ampicillin, tetracycline or other antibiotic resistance or using other markers depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell, D.B., et al., Proc Natl Acad Sci (USA) (1969) 62:1159, optionally following
20 chloramphenicol amplification (Clewell, D.B., J Bacteriol (1972) 110:667). Several mini DNA preps are commonly used, e.g., Holmes, D.S., et al., Anal Biochem (1981) 114:193-197 and Birnboim, H.C., et al., Nucleic Acids Res (1979) 7:1513-1523. The isolated DNA is
25 analyzed by restriction and/or sequenced by the dideoxy nucleotide method of Sanger, F., et al., Proc Natl Acad Sci (USA) (1977) 74:5463 as further described by Messing et al., Nucleic Acids Res (1981) 9:309, or by the method
30 of Maxam et al., Methods in Enzymology (1980) 65:499.

The invention will be further described by the following examples. These are provided only to illustrate embodiments of the invention and are not to be construed as limitations on the invention's scope.

35

SUBSTITUTE SHEET

Example 1

Isolation of a Genomic Clone and cDNA Clones
Encoding β -amyloid Core Protein
and β -amyloid-related Proteins

5

A human genomic library in Charon 4A λ -phage was screened using a six-fold degenerate 38 mer probe corresponding to the first 13 amino acids of the 28 amino acid sequence N-terminal sequence. This probe,

10

3'CTGCGACTTAAGGCCGTGCTGAGICCGATGCTTCAGGTT-5'

G

T

15

wherein I is inosine, when used to screen the human genomic library yielded a strongly hybridizing colony designated λ SM2. λ SM2 DNA was isolated and partially sequenced with the results shown in Figure 2. The sequenced portion is only a small fraction of the

20

approximately 10-20 kb insert in the phage isolated from the genomic library.

25

A probe was constructed from the HindIII/RsaI fragment representing approximately positions 201-294. The genomic probe was used to screen a cDNA library prepared in λ gt10 using standard techniques from brain tissue of a 55 year old man with no evidence of Alzheimer's disease. The three clones designated λ SM2W4, λ SM2W3 and λ SM2W9 were identified.

30

Example 2

The genomic and cDNA sequences described above can be used to prepare recombinant protein in an efficient expression system. Genomic DNA can be utilized in cells, such as mammalian cells, capable of processing introns. Bacterial cells can be utilized for expression of cDNA sequences.

35

SUBSTITUTE SHEET

Bacterial Expression of β -Amyloid-Related Protein
and Production of Antisera

A. Construction of plasmid pAPCP118-3.

5 Construction of an E. coli expression vector
for human β -amyloid-related protein (655-751) required
the joining of three DNA fragments: (1) a plasmid
backbone (consisting of replication functions,
ampicillin resistance gene, tryptophan
10 promoter/operator, ribosome binding site, DNA encoding
the amino terminus of E. coli β -galactosidase (7 amino
acids) followed by six threonine residues, and
transcription termination signals), (2) a fragment of
the β -amyloid-related DNA encoding amino acids 655-728,
15 of Figure 1 and (3) a synthetic fragment of the
 β -amyloid-related DNA encoding amino acids 729-751 of
Figure 1 and the stop codon UAA.

The plasmid backbone referred to above is
derived from pTRP83-1. Plasmid pTRP83-1 is a bacterial
20 expression plasmid which was constructed in the
following manner:

1. Construction of the Synthetic Tryptophan Operon
Promoter and Operator Regulatory Sequence

25 The ten oligodeoxynucleotides shown in Figure
14 were synthesized by the phosphotriester method and
purified. 500 pmole of each oligodeoxynucleotide except
1 and 10 were phosphorylated individually in 20 μ l
containing 60 mM Tris-HCl, pH 8, 15 mM DTT, 10 mM MgCl₂,
30 20 μ Ci of [λ -³²P]-ATP and 20 units of polynucleotide
kinase (P/L Biochemicals) for 30 min. at 37°C. This was
followed by the addition of 10 μ l containing 60 mM
Tris-HCl, pH 8, 15 mM DTT, 10 mM MgCl₂, 1.5 mM ATP and
20 additional units of polynucleotide kinase followed by
35 another 30 min incubation at 37°C. Following incubation
the samples were incubated at 100°C for 5 min. 500

SUBSTITUTE SHEET

pmole of oligodeoxynucleotides 1 and 10 were diluted to 30 μ l in the above buffer without ATP.

16.7 pmole of each oligodeoxynucleotide constituting a double stranded pair (e.g. oligodeoxynucleotides 1 and 2, 3 and 4 etc. Figure 14 were mixed and incubated at 90°C for 2 min followed by slow cooling to room temperature. Each pair was then combined with the others in the construction and extracted with phenol/chloroform followed by ethanol precipitation. The oligodeoxynucleotide pairs were reconstituted in 30 μ l containing 5 mM Tris-HCl, pH 8, 10 mM MgCl₂, 20 mM DTT, heated to 50°C for 10 min and allowed to cool to room temperature followed by the addition of ATP to a final concentration of 0.5 mM. 800 units of T4 DNA ligase were then added and the mixture incubated at 12.5°C for 12-16 hours.

The ligation mixture was extracted with phenol/chloroform and the DNA ethanol precipitated. The dried DNA was reconstituted in 30 μ l and digested with EcoRI and PstI for 1 hour at 37°C. The mixture was extracted with phenol/chloroform and ethanol precipitated followed by separation of the various double stranded DNA segments by electrophoresis on an 8% polyacrylamide gel, according to the method of Laemmli et al., Nature (1970) 227:680. The DNA fragments were visualized by wet gel autoradiography and a band corresponding to approximately 100 bp in length was cut out and eluted overnight as described. The excised synthetic DNA fragment was ligated to plasmids M13-mp8 or M13-mp9 (Messing and Vieira, (1982) Gene 19:259-268) similarly digested with EcoRI and PstI, and submitted to dideoxynucleotide sequence analysis to confirm the designed sequence. This designed sequence contains the promoter (-35 and -10 regions) and operator regions of the tryptophan operon (trp) as well as the ribosome binding region of the tryptophan operon leader peptide.

SUBSTITUTE SHEET

Analogous sequences to that shown in Figure 14 have been proven to be useful in the expression of heterologous proteins in E. coli (Hallewell, R.A., and Emtage, S., Gene (1980) 9:27-47, Ikehara, M., et al., Proc Natl Acad Sci (USA) (1984) 81:5956-5960).

2. Construction of the Synthetic trp Promoter/Operator Containing Plasmid pTRP233

Plasmid pKK233-2 (Amann, E. and Brosius, J., Gene (1985) 40:183 was digested to completion with NdeI and the ends were made blunt with 5 units of E. coli polymerase I, Klenow fragment (Boehringer-Mannheim, Inc.) and the addition of all four dNTPs to 50 μ M. This was incubated at 25°C for 20 min. Following phenol/chloroform extraction and ethanol precipitation, the NdeI-digested DNA was ligated and transformed into E. coli (Nakamura, K., et al., J Mol Appl Genet (1982) 1:289-299). The resulting plasmid lacking the NdeI site was designated pKK-233-2-Nde.

Twenty nanograms of plasmid pKK-233-2-Nde was digested to completion with EcoRI and PstI followed by calf intestinal phosphatase treatment. Fifty nanograms of the synthetic trp promoter/operator sequence obtained from M13 RF, by digesting with EcoRI and PstI, were mixed with ten nanograms of EcoRI and PstI-digested pKK-233-2-Nde and ligated with T4-DNA ligase, followed by transformation into E. coli JA221 lpp⁻/I⁻lacI. Transformants were screened for the presence of plasmid DNA containing the 100 bp EcoRI-PstI synthetic trp promoter/operator; the correct plasmid was then isolated and designated pTRP233.

pTRP233 was digested with EcoRI, the ends blunted with Klenow, and ligated to remove the EcoRI restriction site. The plasmid was next digested with NdeI and HindIII and an NdeI-EcoRI-HindIII fragment

SUBSTITUTE SHEET

encoding β -gal-(thr)6 between the NdeI and EcoRI sites was inserted to create plasmid pTRP83-1.

5 Plasmid pTRP83-1 was then digested with EcoRI and HindIII restriction endonucleases and the digest was electrophoresed in a 0.6% agarose gel (Maniatis, T., et al., at pp. 157-160). The large fragment containing the plasmid backbone was eluted from the gel. Next, the EcoRI fragment containing β -amyloid-related sequences
10 derived from λ SM2W3 (corresponding to amino acids 655-751 of Figure 1 and 500 bp of 3'-untranslated sequences) was digested next with HaeII restriction endonuclease and electrophoresed in a 12% polyacrylamide gel. The approximately 230 bp EcoRI-HaeII fragment
15 (containing β -amyloid-related sequences encoding amino acids 655-728) was eluted. The remaining portion of the β -amyloid-related sequences of Figure 1 encoding amino acids from 728-751 were prepared using the six oligodeoxynucleotides illustrated in Figure 9. 500
20 pmole of each oligodeoxynucleotide except for 1 and 6 were phosphorylated individually. 167 pmole of each oligodeoxynucleotide constituting a pair (e.g. 1 and 2, 2 and 3, etc.) were mixed and incubated at 90°C for 2 min followed by slow cooling to room temperature. Each pair was then combined with the others and extracted
25 with phenol/chloroform followed by ethanol precipitation. The pairs were reconstituted in 30 μ l containing 5 mM Tris-HCl, pH 8, 10 mM MgCl₂, 20 mM DTT, heated to 50°C for 10 min, and allowed to cool to room temperature. ATP was added to a final concentration of
30 0.5 mM, 800 units of T4 DNA ligase was added and the mixture incubated at 12°C for 12-16 hr. The ligation was electrophoresed in a 12% polyacrylamide gel and the 79 bp HaeII-HindIII synthetic fragment was eluted.

35 The EcoRI-HindIII plasmid backbone of pTRP83-1, the approximately 230 bp EcoRI-HaeII β -amyloid cDNA fragment, and the 79 bp synthetic HaeII-HindIII

SUBSTITUTE SHEET

5 β -amyloid fragment were ligated at 12°C for 12-16 hr. E. coli strain MC1061 was transformed with the ligation mixture (Maniatis, T., et al., pp. 250-251) and the resulting ampicillin resistant colonies were grown overnight in 1 ml of L broth supplemented with 100 μ g/ml ampicillin sulfate. Plasmid DNA was prepared by the alkaline lysis method (Maniatis et al., pp. 368-369). Plasmids were screened for the correct inserts by digestion with EcoRI and HindIII. A plasmid releasing an approximately 300 bp EcoRI-HindIII fragment was designated pAPCP118-3.

B. Expression of β -Amyloid-Related Fusion Polypeptide (655-751).

15 The plasmid pAPCP118-3 expresses a 110 amino acid β -galactosidase-threonine- β -amyloid-related fusion protein under the control of the E. coli tryptophan promoter/operator. E. coli strain W3110 was transformed with plasmid pAPCP118-3 and one of the resulting
20 ampicillin resistant colonies was grown for 12-16 hr at 37°C in media containing M9 minimal salts (Miller, J., Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) supplemented with glucose (0.4%), thiamine (2 μ g/ml), $MgSO_4 \cdot 7H_2O$ (200
25 μ g/ml), tryptophan (40 μ g/ml), casamino acids (0.5%), and ampicillin (100 μ g/ml). Expression was induced by dilution of the culture 100-fold into new media with reduced tryptophan (4 μ g/ml) for 2 hr followed by the addition of 3- β -indoleacrylic acid at a final
30 concentration of 25 μ g/ml. Expression of β -gal-thr- β -amyloid (655-751) fusion protein occurs at the level of 10-20% of total cell protein, and is present in the form of inclusion bodies which can be visualized by phase contrast microscopy (1000 x
35 magnification). The cells were harvested 6 hr after the addition of the 3- β -indoleacrylic acid by

SUBSTITUTE SHEET

centrifugation, washed with 10 mM Tris-HCl, pH 7.5, and the cell pellet frozen at -20°C.

5 C. Purification of Beta-gal-thr-8-Amyloid (655-751)
Fusion Protein for Preparation of Antiserum.

10 A cell pellet from 500 ml of culture was resuspended in 40 ml of 10 mM Tris-HCl, pH 7.5, 0.6 M NaCl, and incubated with 8 mg of lysozyme and the protease inhibitors phenylmethylsulfonylfluoride (PMSF) and aprotinin (0.5 mM and 25 µg/ml respectively) for 10 min at 4°C. Solutions of the two detergents, sodium deoxycholate (480 µl of 10% solution) and NP-40 (240 µl of 20% solution), were then added for an additional 10 min incubation at 4°C. The cell pellet was sonicated to 15 disrupt cells and free inclusion bodies. RNase (10 µg/ml) and DNase (10 µg/ml) were added and the mixture stirred for 30 min at room temperature to digest RNA and DNA. The inclusion bodies (and some cell debris) were collected by centrifugation for 10 min at 5000 rpm 20 (SA600 rotor). The supernatant was discarded and the pellet boiled in protein gel sample buffer for 20 min to solubilize the fusion protein. The fusion protein was then purified by electrophoresis in 12% SDS/ polyacrylamide gels (Laemmli, U.K., Nature (1970) 25 227:680). The edges of each gel were removed and stained with Coomassie blue to visualize the 15 kilodalton (kD) fusion protein. They were then realigned with the gel so that the region of the gel containing the fusion protein could be excised. The 30 polyacrylamide was then crushed through a series of needles (16 gauge down to 22 gauge) with the addition of physiological saline to keep the polyacrylamide moist. The polyacrylamide/fusion protein crush was mixed with adjuvant [RIBI(RAS)] just prior to immunization of the 35 rabbits. Approximately 150-200 µg of fusion protein was administered per animal for the first immunization.

SUBSTITUTE SHEET

Subsequent immunizations use 50-100 µg of fusion prot in.

5 D. Western Blot Analysis of β-Amyloid Synpep Antisera
Using Beta-gal-thr-β-Amyloid (655-751) Fusion
Protein.

10 Cell pellets of E. coli W3110 (pAPCP118-3) and W3110 (pTRP83-1) cultures induced with 3-β-indoleacrylic acid were boiled in Laemmli gel sample buffer and electrophoresed in 12% SDS polyacrylamide. The second transformed strain is a negative control which contains all proteins except for the β-gal-thr-β-amyloid (655-741) fusion. The gels were then electroblotted to nitrocellulose, incubated first with APCP synpep
15 antisera collected from immunized rabbits, and then incubated with ¹²⁵I-Staphylococcus protein A to identify bound antibody (Johnson, D.A., et al., Gene Anal Tech (1984) 1:3). An autoradiogram was generated from these nitrocellulose filters which demonstrated
20 crossreactivity between anti-APCP3 serum and the fusion protein, Synpep APCP3 is comprised of amino acids 705-719 of Figure 1 which are included within the β-amyloid portion of the fusion protein. Cross-reactivity was also observed for other β-amyloid
25 synpep antisera.

Example 3

30 Generation of Polyclonal and Monoclonal Antibodies
Against β-Amyloid-Related Protein Using Live
Recombinant Vaccinia Virus

1. Construction of Plasmid pFL4T4B.

35 The construction of the plasmid which allowed for the generation of polyclonal and monoclonal antibodies is schematically represented in Figure 10.

SUBSTITUTE SHEET

Plasmid pGEM-3TM (Promega-Biotec) was EcoRI-digested and treated with calf intestinal phosphatase in accordance with Maniatis et al. Fifty nanograms of the purified 1.06 kb EcoRI fragment derived from λ APCP168i4 were
5 mixed with 10 nanograms EcoRI-digested pGEM-3TM and incubated with T4 DNA ligase in a total volume of 20 μ l for 30 min at 25°C. E. coli strain MC1061 was made competent for transformation by the CaCl₂ method and transformed with the ligation mix. Resulting ampicillin
10 resistant colonies were grown overnight in 2 ml L-amp broth from which plasmid DNA was prepared by the Triton lysis method (Maniatis et al.). Plasmids were screened for the correct orientation by digestion with HindIII. A plasmid having 150 and 3700 bp HindIII restriction
15 fragments was chosen and designated p4BI. The resulting plasmid p4BI was digested with HindIII, religated with T4 ligase for 30 minutes at 25°C and competent MC1061 cells were transformed with the ligation mixture. Plasmids were screened for loss of the 130 bp HindIII
20 fragment by EcoRI digestion. A plasmid containing a single EcoRI site was chosen and designated p4BARI. Ten nanograms of plasmid p4BARI was EcoRI-digested, treated with calf intestinal alkaline phosphatase, and ligated with 100 nanograms of the purified ~2 kb EcoRI fragment
25 derived from λ APCP168i4. The ligation mixture was used to transform competent MC1061 cells. Resulting ampicillin-resistant colonies were grown overnight in L-amp broth and plasmid DNA was prepared. Plasmids were screened for the correct orientation by digestion with
30 BamHI and HindIII. A plasmid having a 1.5 kb BamHI and an ~1.5 kb BamHI-HindIII fragment was chosen and designated p4T4B. Plasmid p4T4B was digested with SmaI and XmnI and the resulting ~2.7kb fragment was eluted from 0.8% agarose followed by ethanol precipitation,
35 dried in vacuo and resuspended in dH₂O.

SUBSTITUTE SHEET

Five µg of the vaccinia virus expression vector pSC11 (Chakrabarti et al., Mol Cell Biol (1985) 5:3403-3409) were digested to completion with SmaI followed by treatment with calf intestinal phosphatase. Five hundred nanograms of the purified ~2.7 kb SmaI-XmnI fragment derived from p4T4B were mixed with fifty nanograms of SmaI-digested pSC11 and incubated with T4 DNA ligase in a total volume of 20 µl for 16 hours at 15°C overnight. E. coli strain MC1061 was transformed with the ligation mix. Resulting ampicillin resistant colonies were grown overnight and plasmid DNA was isolated by the rapid boiling method (Maniatis et al.). Plasmids were screened for insertion and correct orientation by digestion with EcoRI. A plasmid having both an ~2500 bp and an ~600 bp EcoRI fragment was chosen and designated pFL4T4BV.

Monoclonal and polyclonal antibodies against full length β-amyloid-related protein are generated by using a novel method described by Yilma, T., et al., (Hybridoma (1987) 6:329-337). Briefly, the method enables the production of antibodies to a specified protein without the need for a purified antigen (protein) in either the immunization or screening phase of the procedure. The methods make use of the vaccinia virus cloning vectors (Smith et al., Nature (1983) 302:490-495) which can be genetically engineered to carry isolated genes. The infectious recombinant vaccinia virus may then be used to immunize mice. Two weeks after infection, mice are sacrificed and their spleen cells are fused with myeloma cells for monoclonal antibody production as described in the classical approach developed by Kohler and Milstein Nature (1973) 256:495. Alternatively, rabbits can be conventionally immunized with the infectious vaccinia virus recombinant to generate polyclonal antisera.

SUBSTITUTE SHEET

5 Ten µg of plasmid p4T4BV is used to transfect
CV-1 monkey kidney cells infected with wild-type
vaccinia virus according to standard methods (Mackett et
al., J Virol (1984) 49:857-864). TK⁻ recombinants are
10 isolated by plaque assay on TK⁻ cells in the presence of
25 µg/ml Bromodeoxyuridine (BUDR). For plaque assays
involving blue color production, as in the case of the
pSC11 vaccinia virus co-expression vector, 300 µg of
X-Gal per milliliter is placed in the agarose overlay,
15 and plaques visualized after 4-6 hrs at 37°C. Plaques
are purified two to three times in succession. DNA from
the recombinant virus is examined by restriction
endonuclease analysis and DNA hybridization to
32P-nick-translated 2091 bp EcoRI fragment from
λAPCP168i4 to confirm the predicted structure.

Recombinant virus carrying the complete
β-amyloid-related cDNA sequence of λAPCP168i4 is
isolated and amplified to high titer ($1 \times 10^{8-9}$ pfu/ml).
These recombinant viruses are used to immunize rabbits
20 and mice for the subsequent production of polyclonal and
monoclonal antibodies respectively, against full length
β-amyloid-related protein(s) using well established
methods or they can be used for the direct expression of
the recombinant protein. The various antisera are
25 screened either for their ability to specifically
immunoprecipitate the correct size protein from
35S-methionine-labeled CV-1 cells which have been
infected with an β-amyloid-related protein virus
recombinant or for their ability to detect denatured
30 protein on a western blot of similar cells which have
not been exposed to radiolabeled amino acid.

35

SUBSTITUTE SHEET

Example 4Expression of β -Amyloid-Related Protein
(1-751) in Cultured Mammalian Cells

5 To facilitate the expression of
 β -amyloid-related protein in mammalian cells, a plasmid
is constructed such that the coding segment for the
protein is fused to a powerful regulated promoter
derived from the human metallothionine II (hMTII) gene.
10 This procedure is performed in two steps. First an
expression vector pMTSV40 polyA Bam was derived from
pHG-SV(10) vector by digestion of pHG-SV(10) with
BamHI and SmaI restriction enzymes, followed by
incubation with DNA polymerase I (Klenow fragment) in
15 order to create blunt-ended molecules. The blunt ends
are subsequently ligated to BamHI linkers, cut with
BamHI, and religated to allow for recircularization.
This step removes all of the human growth hormone
genomic sequence from pHG-SV(10) except for most of the
20 3' untranslated region of the mRNA and genomic sequences
encoding putative 3' transcriptional stop and processing
signals. For the mammalian cell expression construct,
pMTSV40 polyA Bam is BamHI-digested, then incubated with
all four nucleotide triphosphates and with DNA
25 polymerase I to create blunt ends. This fragment is
subsequently ligated with the purified 2678 bp SmaI-XmnI
fragment derived from p4T4B (described previously). The
recombinant molecules are introduced into MC1061 by
transformation.
30 Chinese hamster ovary (CHO)-K1 cells are grown
in a medium composed of a 1:1 mixture of F12 medium and
DME medium with 10% fetal calf serum. The competent
cells are co-transformed with the recombinant expression
vector and pSU2:NEO (Southern, P., et al., J Mol Appl
35 Genet (1982) 1:327-341). pSV2:NEO contains a functional
gene conferring resistance to the neomycin analog G418.

SUBSTITUTE SHEET

In the transformation, 500 ng of pSV2:NEO and 5 µg of the recombinant vector are applied to a 60 mm dish of CHO cells as a calcium phosphate-DNA co-precipitate as described by Graham, F.L. and Van der Eb, A.J. Virology (1973) 52:456-467. Growth of the cells in the antibiotic G418 as described by Southern et al. will yield a pool of stably transfected CHO cells containing expression vector DNA with the capacity to express β-amyloid-related mRNA and protein.

Example 5

Expression of β-Amyloid-Related Protein (652-751) in Cultured Mammalian Cells

A mammalian cell expression vector encoding for the production of a β-amyloid-related protein can be constructed as shown in Figure 12 as follows: the p4BARI vector of Figure 10 is linearized by digestion with EcoRI. The vector is mixed with two oligonucleotides having the sequences:

5'-ATTCCCGGGACCATGGATGCAG-3'

3'-GGCCCTGGTACCTACGTCTTAA-5'

and ligated using T4 DNA ligase. These oligonucleotides reconstruct the Met-Asp-Ala codons of λSM2W4 and precede them by EcoRI and SmaI sites and follow them with another EcoRI site.

Competent E. coli strain DH1 cells are transformed with the mixture and ampicillin-resistant bacteria are selected by growth on L-Amp plates. A transformant containing the oligonucleotide pair inserted into the EcoRI site in the proper orientation is selected by standard screening techniques and designated pAW4/W3. Plasmid DNA pAW4/W3 is digested with SmaI and XmnI to remove sequences encoding the

SUBSTITUTE SHEET

β -amyloid-related protein described in Figure 5 and the correct piece is isolated by gel purification.

This piece can then be inserted into the mammalian cell expression vector pMTSV40 polyA Bam which has been linearized with BamHI and rendered blunt-ended as described above in Example 4. The resulting vector, pMT-APCP (652-751) can be used for the production of the β -amyloid-related protein (652-751).

Example 6

Expression of β -Amyloid Precursor in Mammalian Cells

Outlined in Examples 4 and 5 are the construction of an expression system for the β -amyloid-related protein (1-751) driven by the human β -actin promoter. A nearly identical construct was prepared using the purified 2548 bp SmaI-XmnI fragment derived from p4T4B (described previously in Example 3) from which 116 bp from the 5' untranslated region have been deleted. This fragment was inserted into the Sall site behind the human β -actin promoter on a plasmid harboring the neomycin selectable marker for mammalian cell expression and the ampicillin resistance gene for selection of bacterial transformants. This vector, pHbAPr-1-neo, has been described by Gunning et al. (Proc Nat'l Acad Sci USA (1987) 84:4831-4835) and has been modified to remove the EcoRI site from the body of the original vector and to substitute the original polylinker region with a new polylinker containing an EcoRI site in addition to the Sall, HindIII, and BamHI cloning sites originally present. The modified vector is referred to as pAXneoR. The pAXneoR vector was linearized with Sall, the termini filled in using Klenow fragment of DNA polymerase to create blunt-ended molecules. The 2548 bp SmaI-XmI β -amyloid fragment was blunt-ligated into the vector using T4 ligase. The

SUBSTITUTE SHEET

recombinant molecules were introduced into E. coli MC1061 by transformation and a clone displaying the proper orientation was amplified. A similar construction was made using the 695 β -amyloid sequences described by Kang et al. (supra) which places the 695 amyloid protein under control of the human β -actin promoter.

600 μ g total DNA of pAXneo/751 β -amyloid or pAXneo/695 β -amyloid or an equal mass mixture of both plasmid constructs were introduced into 10^7 CHO cells by electroporation (Neumann, J Membrane Biol (1972) 10:279-290; Zimmerman, Biophys J (1973) 13:1005-1013) using a BTX Transfector 100, Bio-Rad sterile, disposal cuvettes and a custom built cuvette holder. G418-resistant cells receiving the exogenous DNA were selected by standard protocols (Southern, 1982, supra) using 500 μ g/ml G418 from Gibco.

The pool of positively transfected cells resistant to G418 from each of the three transfections was characterized with respect to β -amyloid precursor protein expression. Approximately 2×10^6 cells from each pool containing 5 ml of serum-free medium were incubated at 37°C for 48 hr. The conditioned media was removed and the protein precipitated by addition of trichloroacetic acid to a final concentration of 10%. Cells were harvested by scraping, washed in saline buffered with phosphate and resuspended in 50 μ l of buffer for a 30-fold concentration. 25 μ l of each sample was loaded onto a 12.5% polyacrylamide gel (Laemmli, Nature (1970) 227:680-685). The β -amyloid precursor was detected by Western blot analysis (Towbin, Proc Nat'l Acad Sci USA (1979) 76:4350-4354) using standard procedures and β -amyloid-specific polyclonal antibodies generated by recombinant vaccinia virus harboring the β -amyloid 751 cDNA as described in Example 3. Typically, the majority of the approximately 110,000

SUBSTITUTE SHEET

dalton β -amyloid precursor is found to be released into the culture media and very small amounts of the protein is cell-associated. This result is in keeping with the hypothesis of Allsop et al. (Proc Natl Acad Sci USA 5 (1988) 85:2790-2794) proposing that the β -amyloid protein is a secreted prohormone. The apparent molecular weight of 110,000 daltons of the recombinantly expressed β -amyloid protein is similar to that observed by others (Dyrks, T., et al., EMBO J 10 7(4):949-957) using in vitro transcription/translation systems.

The β -amyloid 751 protein cloned into a vaccinia virus as described in Example 3 was also examined for the nature of β -amyloid protein expression. 15 The purified recombinant virus was used to infect 10^6 CV-1 cells at a MOI of 1 under serum-free conditions. 18 hr post infection with the virus, both cells and supernatants were harvested, subjected to polyacrylamide gel electrophoresis and Western blotting using the 20 polyclonal antisera described above. As shown in Figure 15, the β -amyloid 110,000 dalton protein was found to be present in the conditioned media versus associated with the cell.

25

Example 7

Assay to Distinguish Genetic Variants of β -Amyloid-Related Protein mRNA Species

The ability to distinguish between genetic 30 variants of β -amyloid-related protein mRNA species using oligonucleotide probes is demonstrated herein.

A diagnostic assay for Alzheimer's disease might take the form of distinguishing between two 35 closely related genetic variants of β -amyloid-related proteins or their mRNAs, and quantitating the relative levels of expression of these proteins or mRNAs. Figure

SUBSTITUTE SHEET

8 provides an example of the use of the invention sequences to provide a standard for the diagnostic assay.

5 Total cellular RNA or cytoplasmic RNA was prepared from human cells in culture or human brain tissue (Alzheimer's brain or normal brain) with or without removal of nuclei (cytoplasmic or total, respectively) by the guanidine thiocyanate/CsCl method as described by Maniatis et al. The samples
10 corresponding to the numbering in Figure 8 are: (1) total RNA from IMR-32 cells (ATCC #CCL127), a mixed neuroblastoma and fibroblast culture; (2) total RNA from MRC5 cells (ATCC #CCL171), a normal fibroblast; (3)
15 total RNA from HeLa cells (ATCC #CCL2.2), an epitheloid cell; (4) cytoplasmic RNA from MRC5 cells; (5) cytoplasmic RNA from HeLa cells; (6) total RNA from HL-60 cells (ATCC #CCL240), a promyelocytic leukemia; (7) total RNA from HL-60 cells which have been treated with 12-tetra-decanoyl-phorbol-13-acetate to induce
20 differentiation of the cells to macrophages; (8) total RNA from normal cerebellum samples; (9) total RNA from normal frontal cortex samples; (10) total RNA from an Alzheimer's individual's frontal cortex; and (11) total RNA from a normal parietal cortex. RNA was fractionat d
25 by oligo-dT cellulose chromatography, electrophoresed on a formaldehyde agarose gel, and blot-transferred to nitrocellulose (all as described in Maniatis et al.). Filters were baked, prehybridized and hybridized to the indicated probes according to standard protocols.
30 The probes indicated are: (1) Junction, a 30 base oligonucleotide #2733, specific for the Kang et al. sequence, as described above in the detailed description of the invention; (2) Insert, a 60 base oligonucleotide #2734 specific for the 8-amyloid-related sequences
35 described in Figure 1, and as described above; and (3) an 1800 bp human actin cDNA insert, isolated from the

SUBSTITUTE SHEET

5 plasmid pHFBA-1 (Pont , P., et al., Nuc Acids Res (1984)
12:1687-1696. Oligonucleotide probes were end-label d
with [³²P]-dCTP by incubation with terminal transferase
according to manufacturer's suggestions. Actin ins rt
10 was radiolabeled with [³²P]-CTP by nick-translation.
After hybridization, the filters hybridized to
oligonucleotides were washed at 1 x S.S.C., 55° C. The
filter hybridized to actin was washed at 0.1 x SSC at
55°C. Filters were then exposed to X-ray film to
15 produce the autoradiogram shown. The insert probe
detects the β-amyloid related protein mRNA described in
Figure 1 in all samples examined. The junction probe
detects the β-amyloid-related mRNA described by Kang et
al. in all cells except HeLa and MRC5. The actin probe
is a control which is expected to hybridize to an
abundant RNA in all cells.

Example 8

20 Bacterial Expression of β-Amyloid-Related Protein (289-345)

A. Construction of Plasmid pAPCP125-2.

25 A synthetic gene was assembled according to
the teaching of Example 2 for β-amyloid-related protein
(289-345) from three pairs of oligodeoxyribonucleotides
(illustrated in Figure 9D) utilizing E. coli preferred
codon choice for highly expressed genes, and a
hydroxylamine cleavage site (Asn-Gly) was inserted
30 preceding amino acid 289 (Glu) to permit release of the
polypeptide from a fusion protein. The expression
vector pTRP83-1 was digested with restriction
endonucleases EcoRI and HindIII and the linearized
plasmid purified from a 0.6% agarose gel. Fifty μg of
35 plasmid DNA and 200 μg of synthetic gene DNA were
ligated using T4 DNA ligase and E. coli MC1061 was

SUBSTITUTE SHEET

transformed with the ligation. Ampicillin-resistant colonies were grown overnight in L broth containing 100 µg/ml ampicillin and alkaline plasmid preps were made. The resulting plasmid DNA was digested with BamHI restriction endonuclease to confirm insertion of the gene within the vector by release of an approximately 350 bp fragment. One plasmid receiving the synthetic gene insert was designated pAPCP125-2.

10 B. Expression of β -Amyloid-Related Fusion Polypeptide (289-345).

The plasmid pAPCP125-2 is designed to express a 74 amino acid

15 β -galactosidase-threonine- β -amyloid-related fusion protein under the control of the E. coli tryptophan promoter/operator. E. coli strain W3110 is transformed with plasmid pAPCP125-2 and one of the resulting ampicillin resistant colonies is grown as described in Example 2. Expression is induced by the addition of 20 3- β -indoleacrylic acid at a final concentration of 25 µg/ml. After 5 hrs induction, a 1 ml aliquot of cells is withdrawn from the culture, harvested by centrifugation, then boiled in 100 µl of Laemmli protein sample buffer for electrophoresis through a 16% 25 SDS-polyacrylamide gel by standard methodologies. Assessment of inclusion body formation is made by phase contrast microscopy (1000X). Expression levels are estimated by Coomassie blue staining of the gel followed by densitometer scan to quantitate the intensity of 30 protein bands. Cells to be used for protein purification are harvested by centrifugation, washed with 10 mM Tris-HCl, pH 7.5, and the cell pellet frozen at -20°C until needed.

35

SUBSTITUTE SHEET

C. Purification of Beta-gal-thr- β -amyloid-related Protein (289-345)

5 The fusion protein is purified as described for the β -gal-thr- β -amyloid-related (655-751) fusion protein (Example 2) in the absence of PMSF and aprotinin. A series of washes from 2 M urea to 4 M urea removes other proteins and further enriches fusion protein found in inclusion bodies. If further
10 purification is desired, the fusion protein is solubilized in 6-8 M urea, and a gel filtration or ion exchange chromatography step is included. If not, the fusion protein is solubilized in 6 M guanidium hydrochloride with hydroxylamine under the conditions described by Moks et al., Biochem (1987) 26:5239-5244
15 for cleavage between the Asn and Gly residues releasing β -amyloid-related protein (289-345) with a Gly residue at its amino-terminus. The cleaved peptides are purified by reversed phase high pressure liquid chromatography, ion exchange or gel filtration
20 chromatography. The purified β -amyloid-related protein is then reduced and reoxidized by methods described by Tan and Kaiser, J Org Chem (1976) 41:2787 and Biochemistry (1977) 16:1531-1541, to reform disulfide bonds between the six Cys residues. Successful
25 reoxidation of bovine pancreatic trypsin inhibitor (aprotinin) also containing six Cys residues and produced in E. coli has been accomplished by these methods (von Wilcken-Bergmann et al., EMBO (1986) 5:3219-3225).

30

Example 9

Construction and Expression of the Inhibitor Protein

35 DNA sequences coding for each of the two chimeric proteins were assembled from synthetic oligonucleotides. The sequences of the oligonucleotides

SUBSTITUTE SHEET

used are shown in Figure 16. The sequence of the phoA signal peptide (Figure 16B) is from Kikuchi et al. (supra), the sequence for ompA signal peptide (Figure 16A) is from Beck and Bremer, (supra). Each
5 oligonucleotide was treated with kinase (except for the 2 outside 5' ends).

All 8 oligonucleotides encoding either the phoA or ompA fusions were mixed together and treated with ligase. Analytical gels showed a new band of the
10 expected length (~250 bp). The ligated constructs were then ligated into the NdeI-HindIII sites of the vector pTRP233. The ligated vectors were transfected into E. coli strain MC1061 and Amp^R colonies selected. Plasmid minipreps showed recombinant plasmids with the correct
15 restriction map. Miniprep DNA was used to transfect strains W3110 and JE5505. Small scale cultures of each of the three strains were grown and induced with IAA overnight. Culture supernatants were examined for trypsin inhibitory activity. Trypsin is assayed for its
20 ability to hydrolyze the synthetic substrate N-benzoyl-D-arginine-p-nitroaniline to release p-nitroaniline (pNA). The release of pNA as a function of time is easily monitored in a spectrophotometer and can be quantitated to measure trypsin activity. The
25 inhibitor is detected in this assay by virtue of its ability to bind to trypsin and prevent hydrolysis of the substrate by trypsin. Inhibitory activity was detected in the culture medium for both ompA and phoA constructs in JE5505 but not W3110 or MC1061. Expression levels
30 appeared to be higher with the phoA construct and so only this construct was used for subsequent experiments.

A time course study was conducted in which levels of inhibitor in the medium were assayed and rates of synthesis of the inhibitor were monitored by
35 ³⁵S-methionine incorporation into inhibitor protein. This study showed that synthesis declined to zero

SUBSTITUTE SHEET

between 4 and 6 hrs after induction with IAA while inhibitor protein accumulated in the medium out to 8 hrs post-induction. This lag is presumed to represent the time required for protein to diffuse from the periplasm through the outer membrane into the medium. Levels of inhibitor in the medium appeared to remain stable from 8 to 24 hrs post-induction.

Example 10

Purification of Inhibitor Protein

A 5 liter culture of E. coli JE5505 transformed with the phoA construct was grown overnight, induced at OD₅₅₀=0.1, and harvested at 8 hrs after induction with IAA. Cells were centrifuged out and discarded. The supernatant was filtered through 8 µm and 0.45 µm filters and passed through a trypsin Sepharose affinity column (total 10 ml Sepharose, 6 mg/ml trypsin on Sepharose, 5 ml/min flow rate, 4°C). The column was washed with 0.1 M sodium acetate buffer, pH 4, containing 0.3 M sodium chloride (NaCl) and 0.01 M calcium chloride (CaCl₂) to remove nonspecifically bound protein. The inhibitor was eluted with a buffer of 0.1 M hydrochloric acid-0.5 M NaCl-0.01 M CaCl₂, pH 1.25. Alternatively, rather than using trypsin affinity column as the affinity matrix, a trypsin bead slurry may be employed. To 5 liters of the E. coli JE5505 supernatant, about 20 ml of a trypsin Sepharose bead slurry were added and stirred gently with a mixer (at 300 rpm, 1 hr, room temperature). The mixture was decanted into a scintered glass funnel and the liquid aspirated from the beads. Using approximately 4 liters of 20 mM Tris-HCl, pH 7.5, the beads were re-equilibrated and then washed with 0.1 M acetic acid-0.3 M NaCl, pH 4.5. The beads were re-equilibrated using 20 mM Tris-HCl, pH 7.5 and then the protease

SUBSTITUTE SHEET

inhibitor was eluted using about 80 mls of 0.1 M HCl-0.5 M NaCl, pH 1.25. The eluate was neutralized using approximately 2.5 mls of 2 M Tris base, pH 10.0.

5 The trypsin affinity column eluate was injected onto a Jones Chromatography APEX-WP[®] butyl HPLC column (1 cm ID x 25 cm length) equilibrated in 20% acetonitrile-0.1% trifluoroacetic acid-80% water. A linear gradient to 60% acetonitrile/0.1% TFA in H₂O was run to eluate the inhibitor. The inhibitor elutes in a major peak (peak 4) and a minor peak (peak 2). Both are active in the trypsin inhibition assay, both appear homogeneous on the protein sequencer (40 cycles for peak 4, 49 cycles for peak 2) and both have the amino acid composition expected for the A4 inhibitor. Treatment of peak 2 with 10 mM DTT (dithiothreitol) causes partial conversion of peak 2 to peak 4, suggesting that peak 2 may rise by oxidation of methionine. In each case the endogenous E. coli signal peptidase had cleaved the chimeric protein at the expected site as shown by the arrows in Figure 16. Mass spectrometric (MS) analysis indicates that peak 4 has a molecular mass of 6,267 daltons, very close to the predicted value of 6,267.7 for full length A4; with 3 disulfide bridges. Since each S-S bridge formed results in loss of 2 H⁺ (= 2 daltons), the number of S-S can be assessed. Peak 2 gives a heterogeneous peak in MS about 80 daltons greater than peak 4, consistent with oxidation. The acid conditions used to elute the protein from the trypsin-Sepharose affinity column will promote oxidation of methionine, however, peak 2 formation is minimized by rapid neutralization using a buffered solution, such as, for example, 2 M Tris base having a pH in the range of about 8 to about 11, preferably pH 10.0, after elution from the trypsin-Sepharose affinity column.

35

SUBSTITUTE SHEET

Example 11A4 Inhibitory Activity

5 The effects of A4 inhibitor on serine- and
thiol- proteases were examined as follows: trypsin
(17,000 units/mg from porcine pancreas), factor Xa and
 α -thrombin (gifts from Dr. Iwanagu, Kyushu University,
Fukuoka, Japan), tryptase and chymase (both from rat
peritoneal mast cells purified as described in Kido et
10 al., Arch Biochem Biophys 239:436-443 (1985)),
 α -chymotrypsin (0.75 U/mg from bovine pancreas),
elastase (33 U/mg from porcine pancreas), papain,
cathepsin B (from rat liver purified as described in
Towatari et al., Eur J Biochem 102:279-289 (1979)),
15 plasmin (0.16 U/mg from human plasma), urokinase (0.75
U/mg from human kidney cells, Sigma Chemical Co.),
tissue kallikrein (50 U/mg from porcine pancreas) or
plasma kallikrein (9.4 U/mg from human plasma) was
preincubated with various concentrations of the
20 inhibitor in a total volume of 1.5 ml of buffer
containing bovine serum albumin (0.1 mg/ml). The
buffers used were as follows: 0.1 M Tris-HCl, pH 7.5,
for trypsin, plasmin and urokinase; 0.1 M Tris-HCl, pH
8.0, for chymase and α -chymotrypsin; 0.1 M Tris-HCl, pH
25 8.0, containing 10 mM CaCl₂ for factor Xa and
 α -thrombin; 0.1 M Tris-HCl, pH 8.5, for tryptase M; 0.1
M Tris-HCl, pH 7.8, for plasma and tissue kallikrein;
0.1 M Tris-HCl, pH 7.0 for elastase; 50 mM acetate, pH
6.0, containing 1 mM EDTA and 4 mM cysteine for papain
and cathepsin B. After preincubation for 5 min at 25°C,
30 7.5 μ l of 20 mM concentrations of the fluorogenic
substrate shown in Table I were added and the residual
activity of each protease was measured in a quartz
cuvette maintained thermostatically at 25°C. The amount
35 of 7-amino-4-methylcoumarin liberated from the
substrates was determined fluorometrically with

SUBSTITUTE SHEET

excitation and emission wavelengths of 380 nm and 460 nm, respectively, in a Hitachi fluorescence spectrophotometer, 650-10MS model, as reported in Kido et al. (1988), supra. Protein concentration was determined with bicinchoninic acid protein assay reagent as described by Smith et al., Anal. Biochem. 150:76-85 (1985).

The K_i values of the A4 inhibitor for various proteases was determined from a Lineweaver-Burk plot of the initial rate of hydrolysis of substrate and are shown in Table I.

SUBSTITUTE SHEET

Table I

	Protease	Substrate ^a	pH	Ki value nM
5	Trypsin	Boc-Phe-Ser-Arg-MCA	7.5	2.7
	Tryptase M	Boc-Phe-Ser-Arg-MCA	8.5	0.22
	Factor Xa	Boc-Ile-Glu-Gly-Arg-MCA	8.0	257.0
10	α -Thrombin	Boc-Val-Pro-Arg-MCA	8.0	NI ^b
	Chymase	Suc ^c -Leu-Leu-Val-Tyr-MCA	8.0	NI
	α -Chymo- trypsin	Suc-Leu-Leu-Val-Tyr-MCA	8.0	8.5
	Elastase	Suc-Ala-Pro-Ala-MCA	7.0	NI
15	Plasmin	Boc-Val-Leu-Lys-MCA	7.5	0.075
	Urokinase	Glt-Gly-Arg-MCA (Glt?)	7.5	NI
	Plasma kallikrein	Z ^d -Phe-Arg-MCA	7.8	73.9
	Tissue kallikrein	Pro-Phe-Arg-MCA	7.8	28.4
20	Papain	Z-Phe-Arg-MCA	6.0	NI
	Cathepsin B	Z-Phe-Arg-MCA	6.0	NI

25 ^a Provided by the Protein Research Foundation, Osaka, Japan.

^b NI, no inhibition at a concentration of 1 μ M A4 inhibitor.

^c Suc-, succinyl-.

^d Z-; benzyloxycarbonyl.

30

This A4 inhibitor strongly inhibited plasmin ($K_i = 7.5 \times 10^{-11}$ M) from human serum and tryptase M ($K_i = 2.2 \times 10^{-10}$ M) from rat mast cells. It also inhibited pancreatic trypsin ($K_i = 2.7 \times 10^{-9}$ M), α -chymotrypsin ($K_i = 8.5 \times 10^{-9}$ M) and plasma and tissue kallikrein ($K_i = 7.4 \times 10^{-8}$ M and 2.8×10^{-8} M, respectively) but did

35

SUBSTITUTE SHEET

not inhibit chymase or pancreatic elastase. It inhibited factor Xa ($K_i = 2.57 \times 10^{-6}$ M) slightly, but did not inhibit α -thrombin, urokinase, papain or cathepsin B.

5

Example 12
Trypsin Inhibition

Trypsin (30 pM) was preincubated with various concentrations (3-24 pM) of purified A4i inhibitor in 0.1 M Tris-HCl, pH 7.5, containing bovine serum albumin (0.1 mg/ml) at 25°C for 5 min. Residual activities of trypsin were measured with Boc-Phe-Ser-Arg-MCA as substrate.

The plot of the inhibition of trypsin by the purified A4i inhibitor indicated a 1:1 molar reaction of the A4i inhibitor with trypsin.

Example 13
Pharmaceutical IV Composition

A solution of A4i and/or analogs thereof as described above in a phosphate buffered physiological saline solution which contains 0.001% of Tween 80 red 0.01-1% of albumin or mannitol, will provide an intravenous formulation suitable for injection.

Example 14
Pharmaceutical Topical Composition

Pharmaceutically effective topical compositions of the invention are preferably in the form of dressings. Such dressings are external pharmaceutical applications resembling ointments which are generally used as coverings for abraded tissues. The A4i protein and/or analogs thereof can be added to a

SUBSTITUTE SHEET

5 petroleum gauze which is a sterile dressing prepared by
adding sterile molten white petroleum to pre-cut sterile
gauze in a ratio of 60 grams of petroleum to 20 grams of
gauze. The A4i protein or analog can be added to the
10 gauze in any given amount depending on the needs of the
particular patient. However, such a protein is
generally added in a relatively small amount such as in
the range of about 1 to 10 grams per 20 grams of gauze
and 60 grams of petroleum. The topical antibacterial
15 components can be added to the dressing to aid in
preventing infection.

Example 15

Topical Creams

15

Topical creams useful in treating wounds, and
abraded tissues and in providing for transdermal and
transmucousal penetration of A4i proteins and analogs
thereof can be prepared by mixing various inert
20 excipient materials with the A4i protein and/or analogs
thereof generally in a ratio of about 90-99% excipient
by weight to 1-10% protein by weight. The excipient
materials are preferably demulcents which are protective
agents employed primarily to alleviate irritation
25 particularly on mucous membranes and abraded tissue.
Useful demulcents include mucilages, gums, dextrans,
starches, certain sugars, and polymeric polyhydric
glycols. Mucous itself is a natural demulcent and
synthetic mucous creams are known to those skilled in
30 the art which can serve as the excipient base material
to be combined with the protein for topical application.

35

SUBSTITUTE SHEET

Example 16
Ophthalmic Formulations

Ophthalmic formulations can be prepared
5 containing the A4i proteins and/or analogs thereof for
the treatment of abraded ocular tissues. As such ocular
formulations can be prepared by adding 1-10% by weight
of the A4i protein and/or analogs thereof to a
conventional wetting solution for contact lenses. Such
10 solutions are comprised of water and polyvinyl alcohol
as a demulcent that helps protect the eye from
irritation generally caused by contact lenses.

While preferred embodiments of making and
15 using the invention have been described, it will be
appreciated that various changes and modifications can
be made without departing from the invention.

The following cultures have been deposited
with the American Type Culture Collection (ATCC),
20 Rockville, MD, USA for patent purposes. Bacteriophage
phages λ SM2, λ SM2W9, and λ APCP168i4 were deposited under
the conditions specified by the Budapest Treaty on the
International Recognition of the Deposit of
Microorganisms (Budapest Treaty).

	<u>Culture</u>	<u>Accession No.</u>	<u>Deposit Date</u>
	λ SM2	40279	13 November 1986
	SM2W4	40299	29 December 1986
	SM2W3	40300	29 December 1986
30	λ SM2W9	40304	29 January 1987
	λ ACPC168i4	40347	1 July 1987

Availability of the deposited strains are not to be
35 construed as a license to practice the invention in
contravention of the rights granted under the authority
of any government in accordance with its patent laws.

SUBSTITUTE SHEET

Claims

- 5 1. A pharmaceutically acceptable composition having fibrinolytic inhibitory activity, comprising:
a pharmaceutically acceptable excipient; and
a fibrinolytically inhibitory effective amount of the protein having the following amino acid sequences:
- 10 GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle.
- 15 2. A method of inactivating fibrin dissolution at a wound site in a subject, comprising administering to the wound site in need of repair an effective amount of the pharmaceutical composition of claim 1.
- 20 3. The method of claim 2 wherein said pharmaceutically acceptable composition is administered in combination with adhesive fibrin.
- 25 4. A pharmaceutically acceptable composition having thrombolytic activity comprising a thrombolytically effective amount of a protein dispersed in a pharmaceutically acceptable excipient wherein the protein has the following amino acid sequence:
- 30 GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle.
- 35

SUBSTITUTE SHEET

5. A method for inhibiting prothrombin activation in a subject, comprising administering to a subject in need thereof a pharmaceutically effective amount of the composition of claim 4.

5

6. A pharmaceutically acceptable composition having antiinflammatory activity comprising an antiinflammatorily effective amount of a protein dispersed in a pharmaceutically acceptable excipient wherein the protein has the following amino acid sequence:

10

15

GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle.

7. A method for inhibiting inflammation in a subject, comprising administering to a subject in need thereof a pharmaceutically effective amount of the composition of claim 6.

20

8. A pharmaceutically acceptable composition having anticarcinomic activity comprising an effective amount of a protein dispersed in a pharmaceutically acceptable excipient wherein the protein has the following amino acid sequence:

25

30

GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle.

9. A method for inhibiting tumor growth in a subject, comprising administering to a subject with tumor growth a pharmaceutically effective amount of the composition of claim 8.

35

SUBSTITUTE SHEET

10. A pharmaceutically acceptable composition having a fibrinolytic inhibitory activity as claimed in claim 1, wherein the protein is an isolated native, cloned recombinant or synthetic, biologically active, refolded and substantially purified protein.

11. A pharmaceutically acceptable composition having a fibrinolytic inhibitory activity, comprising:
a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid corresponding to arginine at position 13 in the sequence
GluValCysSerGluGlnAlaGluThrGlyProCysArg₁₃AlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle
is substituted with an aromatic amino acid, the analog being present in a fibrinolytically inhibitory effective amount.

12. The pharmaceutically acceptable composition as claimed in claim 11 wherein said aromatic amino acid is selected from the group consisting of phenylalanine, tyrosine and tryptophan.

13. A pharmaceutically acceptable composition having a fibrinolytic inhibitory activity, comprising:
a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid corresponding to arginine at position 13 in the sequence:

GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle
is substituted with neutral hydrophobic amino acid, the analog being present in a fibrinolytically inhibitory effective amount.

SUBSTITUTE SHEET

14. The protein as claimed in claim 13
wherein said neutral hydrophobic amino acid is selected
from the group consisting of leucine, methionine and
valine.

15. A method of inactivating fibrin
dissolution at a wound site in a subject, comprising:
administering to the wound site in need of
repair a pharmaceutically effective amount of the
composition of claim 13.

16. The method of claim 15 wherein said
pharmaceutically acceptable composition is administered
in combination with adhesive fibrin.

17. A pharmaceutically acceptable composition
having a thrombolytic activity as claimed in claim 4,
wherein the protein is an isolated native, cloned
recombinant or synthetic, biologically active, refolded
and substantially purified protein.

18. A pharmaceutically acceptable composition
having a thrombolytic activity, comprising:
a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid
corresponding to arginine at position 13 in the sequence
GluValCysSerGluGlnAlaGluThrGlyProCysArg₁₃AlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle
is substituted with an aromatic amino acid, the analog
being present in a thrombolytically effective amount.

19. The pharmaceutically acceptable
composition as claimed in claim 18 wherein said aromatic
amino acid is selected from the group consisting of
phenylalanine, tyrosine and tryptophan.

SUBSTITUTE SHEET

20. A pharmaceutically acceptable composition having a thrombolytic activity, comprising:

5 a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid corresponding to arginine at position 13 in the sequence:

10 GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle

15 is substituted with neutral hydrophobic amino acid, the analog being present in a thrombolytically effective amount.

21. The protein as claimed in claim 20 wherein said neutral hydrophobic amino acid is selected from the group consisting of leucine, methionine and valine.

22. A method of dissolving or preventing blood clots in a subject, comprising:

25 administering to the subject in need thereof a pharmaceutically effective amount of the composition of claim 18.

23. The method of claim 22 wherein said pharmaceutically acceptable composition is administered in combination with heparin.

30 24. A pharmaceutically acceptable composition having an anti-inflammatory activity as claimed in claim 6, wherein the protein is an isolated native, cloned recombinant or synthetic, biologically active, refolded and substantially purified protein.

SUBSTITUTE SHEET

25. A pharmaceutically acceptable composition having an anti-inflammatory activity, comprising:
a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid
5 corresponding to arginine at position 13 in the sequence
GluValCysSerGluGlnAlaGluThrGlyProCysArg₁₃AlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle
10 is substituted with an aromatic amino acid, the analog
being present in an amount sufficient to inhibit
inflammation.

26. The pharmaceutically acceptable
15 composition as claimed in claim 25 wherein said aromatic
amino acid is selected from the group consisting of
phenylalanine, tyrosine and tryptophan.

27. A pharmaceutically acceptable composition
20 having an anti-inflammatory activity, comprising:
a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid
corresponding to arginine at position 13 in the
sequence:
25 GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet
IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla
ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe
AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle
is substituted with neutral hydrophobic amino acid, the
30 analog being present in an amount sufficient to inhibit
inflammation.

28. The protein as claimed in claim 27
wherein said neutral hydrophobic amino acid is selected
35 from the group consisting of leucine, methionine and
valine.

SUBSTITUTE SHEET

29. A method of inhibiting inflammation in a subject, comprising:

administering to the subject in need thereof a pharmaceutically effective amount of the composition as claimed in claim 25.

30. The method of claim 29 wherein said pharmaceutically acceptable composition is administered in combination with a non-steroidal anti-inflammatory drug.

31. A pharmaceutically acceptable composition having an anticarcinomic activity as claimed in claim 8, wherein the protein is an isolated native, cloned recombinant or synthetic, biologically active, refolded and substantially purified protein.

32. A pharmaceutically acceptable composition having an antioncogenic activity, comprising:

a pharmaceutically acceptable carrier; and
a protein analog wherein the amino acid corresponding to arginine at position 13 in the sequence

GluValCysSerGluGlnAlaGluThrGlyProCysArg₁₃AlaMet

IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla

ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe

AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle

is substituted with an aromatic amino acid, the analog being present in an amount sufficient to inhibit oncogenic activity.

33. The pharmaceutically acceptable composition as claimed in claim 32 wherein said aromatic amino acid is selected from the group consisting of phenylalanine, tyrosine and tryptophan.

SUBSTITUTE SHEET

34. A pharmaceutically acceptable composition having an anticarcinomic activity, comprising:

a pharmaceutically acceptable carrier; and

a protein analog wherein the amino acid

5 corresponding to arginine at position 13 in the sequence:

GluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMet

IleSerArgTrpTyrPheAspValThrGluGlyLysCysAla

ProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnPhe

10 AspThrGluGluTyrCysMetAlaValCysGlySerAlaIle

is substituted with neutral hydrophobic amino acid, the analog being present in an amount sufficient to inhibit oncogenic activity.

15 35. The protein as claimed in claim 34 wherein said neutral hydrophobic amino acid is selected from the group consisting of leucine, methionine and valine.

20 36. A method of inhibiting carcinomic activity in a subject, comprising:

administering to the subject in need thereof a pharmaceutically effective amount of the composition of claim 32.

25 37. The method of claim 36 wherein said pharmaceutically acceptable composition is administered in combination with an anticarcinomic drug.

30

35

SUBSTITUTE SHEET

1 / 27

FIG. 1 - I

ATG CTG CCC
MET Leu Pro

GGT TTG GCA CTG CTC CTG CTG GCC GCG TGG ACG GCT CGG GCG CTG GAG GTA CCC
Gly Leu Ala Leu Leu Leu Leu Ala Ala Trp Thr Ala Arg Ala Leu Glu Val Pro 20

ACT GAT GGT AAT GCT GGC CTG CTG GCT GAA CCC CAG ATT GCC ATG TTC TGT GGC
Thr Asp Gly Asn Ala Gly Leu Leu Ala Glu Pro Gln Ile Ala MET Phe Cys Gly 30

AGA CTG AAC ATG CAC ATG AAT GTC CAG AAT GGG AAG TGG GAT TCA GAT CCA TCA
Arg Leu Asn MET His MET Asn Val Gln Asn Gly Lys Trp Asp Ser Asp Pro Ser

40 GGG ACC AAA ACC TGC ATT GAT ACC AAG GAA GGC ATC CTG CAG TAT TGC CAA GAA
Gly Thr Lys Thr Cys Ile Asp Thr Lys Glu Gly Ile Leu Gln Tyr Cys Gln Glu 50 60 70

GTC TAC CCT GAA CTG CAG ATC ACC AAT GTG GTA GAA GCC AAC CAA CCA GTG ACC
Val Tyr Pro Glu Leu Gln Ile Thr Asn Val Val Glu Ala Asn Gln Pro Val Thr 80 90

ATC CAG AAC TGG TGC AAG CGG GGC CGC AAG CAG TGC AAG ACC CAT CCC CAC TTT
Ile Gln Asn Trp Cys Lys Arg Gly Arg Lys Gln Cys Lys Thr His Pro His Phe 100 110

GTG ATT CCC TAC CGC TGC TTA GTT GGT GAG TTT GTA AGT GAT GCC CTT CTC GTT
Val Ile Pro Tyr Arg Cys Leu Val Gly Glu Phe Val Ser Asp Ala Leu Leu Val 120

CCT GAC AAG TGC AAA TTC TTA CAC CAG GAG AGG ATG GAT GTT TGC GAA ACT CAT
Pro Asp Lys Cys Lys Phe Leu His Gln Glu Arg MET Asp Val Cys Glu Thr His 130 140

SUBSTITUTE SHEET

2/27

FIG. 1-2

CTT CAC TGG CAC ACC GTC GCC AAA GAG ACA TGC AGT GAG AAG AGT ACC AAC TTG Leu His Trp His Thr Val Ala Lys Glu Thr Cys Ser Glu Lys Ser Thr Asn Leu 150	160
CAT GAC TAC GGC ATG TTG CTG CCC TGC GGA ATT GAC AAG TTC CGA GGG GTA GAG His Asp Tyr Gly MET Leu Leu Pro Cys Gly Ile Asp Lys Phe Arg Gly Val Glu 170	180
TTT GTG TGT TGC CCA CTG GCT GAA GAA AGT GAC AAT GTG GAT TCT GCT GAT GCG Phe Val Cys Cys Pro Leu Ala Glu Glu Ser Asp Asn Val Asp Ser Ala Asp Ala 190	200
GAG GAG GAT GAC TCG GAT GTC TGG TGG GGC GGA GCA GAC ACA GAC TAT GCA GAT Glu Glu Asp Asp Ser Asp Val Trp Trp Gly Gly Ala Asp Thr Asp Tyr Ala Asp 210	
GGG AGT GAA GAC AAA GTA GTA GAA GAA GAG GAG GAA GAA GTG GCT GAG GTG Gly Ser Glu Asp Lys Val Val Glu Val Ala Glu Glu Glu Val Ala Glu Val 220	230
GAA GAA GAA GAA GCC GAT GAT GAC GAG GAT GAT GAT GAT GAT GAT GAT GAT Glu Glu Glu Glu Ala Asp Asp Asp Glu Asp Asp Glu Asp Gly Asp Glu Val Glu 240	250
GAA GAG GCT GAG GAA CCC TAC GAA GAA GAA GCC ACA GAG AGA ACC ACC AGC ATT GCC Glu Glu Ala Glu Glu Pro Tyr Glu Glu Ala Thr Glu Arg Thr Thr Ser Ile Ala 260	270
ACC ACC ACC ACC ACC ACA GAG TCT GTG GAA GAG GTG GTT CGA GAG GTG TGC Thr Thr Thr Thr Thr Thr Glu Ser Val Glu Glu Val Arg Glu Val Cys 280	290

SUBSTITUTE SHEET

3 / 27

FIG. 1-3

TCT GAA CAA GCC GAG ACG GGG CCG TGC CGA GCA ATG ATC TCC CGC TGG TAC TTT
 Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala MET Ile Ser Arg Trp Tyr Phe
 300

GAT GTG ACT GAA GGG AAG TGT GCC CCA TTC TTT TAC GGC GGA TGT GGC GGC AAC
 Asp Val Thr Glu Glu Gly Lys Cys Ala Pro Phe Phe Tyr Gly Cys Gly Gly Asn
 310

CGG AAC AAC TTT GAC ACA GAG TAC TGC ATG GCC GTG TGT GGC AGC GCC ATT
 Arg Asn Asn Phe Asp Thr Glu Glu Tyr Cys MET Ala Val Cys Gly Ser Ala Ile
 330

CCT ACA ACA GCC AGT ACC CCT GAT GCC GTT GAC AAG TAT CTC GAG ACA CCT
 Pro Thr Thr Ala Ala Ser Thr Pro Asp Ala Val Asp Lys Tyr Leu Glu Thr Pro
 350

GGG GAT GAG AAT GAA CAT GCC CAT TTC CAG AAA GCC AAA GAG AGG CTT GAG GCC
 Gly Asp Glu Asn Glu His Ala His Phe Gln Lys Ala Lys Glu Arg Leu Glu Ala
 370

AAG CAC CGA GAG AGA ATG TCC CAG GTC ATG AGA GAA TGG GAA GAG GCA GAA CGT
 Lys His Arg Glu Arg MET Ser Gln Val MET Arg Glu Trp Glu Ala Glu Arg
 390

CAA GCA AAG AAC TTG CCT AAA GCT GAT AAG AAG GCA GTT ATC CAG CAT TTC CAG
 Gln Ala Lys Asn Leu Pro Lys Ala Asp Lys Lys Ala Val Ile Gln His Phe Gln
 400

GAG AAA GTG GAA TCT TTG GAA CAG GAA GCA GCC AAC GAG AGA CAG CAG CTG GTG
 Glu Lys Val Glu Ser Leu Glu Gln Glu Ala Ala Asn Glu Arg Gln Gln Leu Val
 420

GAG ACA CAC ATG GCC AGA GTG GAA GCC ATG CTC AAT GAC CGC CGC CTG GCC
 Glu Thr His MET Ala Arg Val Glu Ala MET Leu Asn Asp Arg Arg Arg Leu Ala
 440

SUBSTITUTE SHEET

4/27

FIG. 1-4

CTG GAG AAC TAC ATC ACC GCT CTG CAG GCT GTT CCT CCT CGG CCT CGT CAC GTG
 Leu Glu Asn Tyr Ile Thr 460
 TTC AAT ATG CTA AAG AAG TAT GTC CGC GCA GAA CAG AAG GAC AGA CAG CAC ACC
 Phe Asn MET Leu Lys Lys Tyr Val 480
 CTA AAG CAT TTC GAG CAT GTG CGC ATG GTG GAT CCC AAG AAA GCC GCT CAG ATC
 Leu Lys His Phe Glu His Val Arg MET Val 500
 CGG TCC CAG GTT ATG ACA CAC CTC CGT GTG ATT TAT GAG CGC ATG AAT CAG TCT
 Arg Ser Gln Val MET Thr His Leu Arg Val Ile Tyr Glu Arg MET Asn Gln Ser 520
 CTC TCC CTG CTC TAC AAC GTG CCT GCA GTG GCC GAG ATT CAG GAT GAA GTT
 Leu Ser Leu Leu Tyr Asn Val Pro Ala Val Ala Glu Ile Gln Asp Glu Val 540
 GAT GAG CTG CTT CAG AAA GAG CAA AAC TAT TCA GAT GAC GTC TTG GCC AAC ATG
 Asp Glu Leu Leu Gln Lys Glu Gln Asn Tyr Ser Asp Val Leu Ala Asn MET 560
 ATT AGT GAA CCA AGG ATC AGT TAC GGA AAC GAT GCT CTC ATG CCA TCT TTG ACC
 Ile Ser Glu Pro Arg Ile Ser Tyr Gly Asn Asp Ala Leu MET Pro Ser Leu Thr 570
 GAA ACG AAA ACC ACC GTG GAG CTC CTT CCC GTG AAT GGA GAG TTC AGC CTG GAC
 Glu Thr Lys Thr Thr Val Glu Leu Leu Pro Val Asn Gly Glu Phe Ser Leu Asp 590
 GAT CTC CAG CCG TGG CAT TCT TTT GGG GCT GAC TCT GTG CCA GCC AAC ACA GAA
 Asp Leu Gln Pro Trp His Ser Phe Gly Ala Asp Ser Val Pro Ala Asn Thr Glu 610

SUBSTITUTE SHEET

5/27

AAC GAA GTT GAG CCT GTT GAT GCC CGC CCT GCT GCC GAC CGA GGA CTG ACC ACT
 Asn Glu Val Glu Pro Val Asp Ala Arg Pro Ala Asp Arg Gly Leu Thr Thr 630

 CGA CCA GGT TCT GGG TTG ACA AAT ATC AAG ACG GAG GAG ATC TCT GAA GTG AAG
 Arg Pro Gly Ser Gly Leu Thr Asn Ile Lys Thr Glu Glu Ile Ser Glu Val Lys 650

 ATG GAT GCA GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT CAT CAT CAA AAA TTG
 MET Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu 660

 GTG TTC TTT GCA GAA GAT GTG GGT TCA AAC AAA GGT GCA ATC ATT GGA CTC ATG
 Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu MET 680

 GTG GGC GGT GTT GTC ATA GCG ACA GTG ATC GTC ATC ACC TTG GTG ATG CTG AAG
 Val Gly Gly Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val MET Leu Lys 700

 AAG AAA CAG TAC ACA TCC ATT CAT CAT GGT GTG GTG GAG GTT GAC GCC GCT GTC
 Lys Lys Gln Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Val 720

 ACC CCA GAG GAG CGC CAC CTG TCC AAG ATG CAG AAC GGC TAC GAA AAT CCA
 Thr Pro Glu Glu Arg His Leu Ser Lys MET Gln Gln Asn Gly Tyr Glu Asn Pro 740

 ACC TAC AAG TTC TTT GAG CAG ATG CAG AAC TAG
 Thr Tyr Lys Phe Phe Glu Gln MET Gln Asn 750

FIG. 1-5

SUBSTITUTE SHEET

6 / 27

FIG. 2-1

TTT TTG TTC AAA ATA GGT AGT AAT TGA	27	AGT TTT AAA TAT AGG GTA TCA TTT TTC	54
Phe Leu Phe Lys Ile Gly Ser Asn .		Ser Phe Lys Tyr Arg Val Ser Phe Phe	
TTT AAG AGT CAT TTA TCA ATT TTC TTC	81	TAA CTT CAG GCC TAG AAA GAA GTT TTG	108
Phe Lys Ser His Leu Ser Ile Phe Phe .		Leu Gln Ala . Lys Glu Val Leu	
GGT AGG CTT TGT CTT ACA GTG TTA TTA	135	TTT ATG AGT AAA ACT AAT TGG TTG TCC	162
Gly Arg Leu Cys Leu Thr Val Leu Leu		Phe MET Ser Lys Thr Asn Trp Leu Ser	
TGC ATA CTT TAA TTA TGA TGT AAT ACA	189	GGT TCT GGG TTG ACA AAT ATC AAG ACG	216
Cys Ile Leu . Leu . Cys Asn Thr		Gly Ser Gly Leu Thr Asn Ile Lys Thr	
		Hind II ↓	
GAG GAG ATC TCT GAA GTG AAG ATG GAT	243	GCA GAA TTC CGA CAT GAC TCA GGA TAT	270
Glu Glu Ile Ser Glu Val Lys MET Asp	1	Ala Glu Phe Arg His Asp Ser Gly Tyr	10
		Eco RI ↓	

SUBSTITUTE SHEET

7 / 27

Rsa I ↓

GAA GTT CAT CAT CAA AAA TTG GTA	297	CGT AAA ATA ATT TAC CTC TTT CCA CTA	324
Glu Val His His Gln Lys Leu Val	18	Arg Lys Ile Ile Tyr Leu Phe Pro Leu Leu	
	15		
TTT GTC TTG CCA AAT GAC CTA TTA	351	CTG GTT CAT CCT GTG CTA GAA ATC AAA	378
Phe Val Leu Pro Asn Asp Leu Leu Thr		Leu Val His Pro Val Leu Glu Ile Lys	
TTA AGG AAA AGA TAA AAA TAC AAT	405	GCT TGC CTA TAG GAT TAC CAT GAA AAC ATG	432
L u Arg Lys Arg . Lys Tyr Asn Ala Cys		Leu . Asp Tyr His Glu Asn MET	
AAG AAA ATA AAT AGG CTA GGC TGA	459	GCG CAG TGG CTC AAG CCT GTA ATC CCA GCA	486
Lys Lys Ile Asn Arg Leu Gly . Ala Gln		Trp Leu Lys Pro Val Ile Pro Ala	

FIG. 2-2

SUBSTITUTE SHEET

8 / 27

FIG. 3-1

GAATTCCCCT	20	30	40	50	60	70
GGGAGCCCAA	GGAATTGGGA	ATGTGTAGCC	CAAGTAAGAC	AAGAACCAGC	AGGAACATGC	
CTCTCCTTAG	GGTCGTGATA	CCTGTTCAAG	GTTTAAATGT	GGAAGGGAGG	ATTAGGCTTG	CTCTGTGTTG
AATCAGGCTC	AAAGGATGGA	AGTTACAGGG	AAGCTGATTC	TGGCTTCATG	TAAAAAAAGG	ACAGTTTGGG
CAGGCAATC	TATCAAAAAA	TGGAGGGGAA	TTGATACATT	CCTCTATGTT	CAACACAGGAA	CTGACAATCT
GCCCCCTGGT	GGGAACACGG	TAGAGAAGAT	GACTTCAAAA	GCCCTTTTCA	TCCTAAAATT	CTGATGTTTG
ATAATTAAAT	GTTATAGCAT	GGACACTGAC	ATTACATTTT	TTTACTTATG	TTTTTGGTTT	TTAAATGACT
CTGCATTTTG	TTTTAAGCTT	CAAAATTATTA	TTTGAATAAT	GAAATTCATC	AGAACAATTA	GTGTTAAGAA
TCATATAGCA	ATTATAGAA	AAGGAAGAGT	TCGTAGGTTA	TAAATTCTGT	TAGTTGCTAA	GAAGCATTTT
TAAAAATTATG	TACTATAGCT	CTTTATTTCAG	CAGACGAACC	AATTACAATC	TGTGTAACTA	GAACACTTGA

SUBSTITUTE SHEET

9/ 27

640 650 660 670 680 690 700
CTAAAAATTAT ATAATTTTCA CAACGCTTCA CTGCATAGAT ACATGAACAT AATTATTTG TAATTGGAAC

710 720 730 740 750 760 770
AAAGCCCCAA AGTAGCAGTT TTGTTCTACC AGGTAATTA TGCTCATTTT TAAAGCCCTT TATTATTATT

780 790 800 810 820 830 840
TCTGAAGTAA TGAGTGCACA TGGAAAAAGA CACATAATAG GCTAAACAAT AAGCCCCGTAA GCCAAGCCAA

850 860 870 880 890 900 910
CATATTCCAG GAACAAATCC TTGCCAACCT CTCAACCAGG ATTTAACTTC TGCTTTTCCC CCAATTTCAA

920 930 940 950 960 970 980
AAATTATAGC ATGTATTTAA AGGCAGCAGA AGCCTTACTT TCAGGGTTCC CTTACCCCTT CATTTCTTTT

990 1000 1010 1020 1030 1040 1050
TGTTCAAAAT AGGTAGTAAT TGAAGTTTAA AATATAGGT ATCATTTTTC TTAAAGAGTC ATTTATCAAT

1060 1070 1080 1090 1100 1110 1120
TTTCTTCTAA CTCAGGCCT AGAAAGAAGT TTTGGGTAGG CTTTGTCTTA CAGTGTATT ATTTATGAGT

1130 1140 1150 1160 1170 1180 1190
AAAACATAAT GGTGTCCCTG CATACTTTAA TTATGATGTA ATACAGGTTC TGGGTTGACA AATATCAAGA

1200 1210 1228
CGGAGGAGAT CTCTGAAGTG AAG ATG GAT GCA GAA TTC
MET Asp Ala Glu Ph

FIG. 3-2

1 2 3 4

UBSTITUTE SHEET

10/27

FIG. 4-1

```

GAA TTC CGA CAT GAC TCA GGA TAT GAA GTT CAT CAT CAA AAA TTG GTG TTC TTT
Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe Phe
3      10      20

GCA GAA GAT GTG GGT TCA AAC AAA GGT GCA ATC ATT GGA CTC ATG GTG GGC GGT
Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu MET Val Gly Gly
30

GTT GTC ATA GCG ACA GTG ATC GTC ATC ACC TTG GTG ATG CTG AAG AAG AAA CAG
Val Val Ile Ala Thr Val Ile Val Ile Thr Leu Val MET Leu Lys Lys Gln
40      50

TAC ACA TCC ATT CAT GGT GTG GTG GAG GTT GAC GCC GCT GTC ACC CCA GAG
Tyr Thr Ser Ile His His Gly Val Val Glu Val Asp Ala Ala Val Thr Pro Glu
60      70

GAG CGC CAC CTG TCC AAG ATG CAG CAG AAC GGC TAC GAA AAT CCA ACC TAC AAG
Glu Arg His Leu Ser Lys MET Gln Gln Asn Gly Tyr Glu Asn Pro Thr Tyr Lys
80      90

TTC TTT GAG CAG ATG CAG AAC TAG ACCCCCGCCA CAGCAGCCTC TGAAGTTGGA CAGCAAACCC
Ph Phe Glu Gln MET Gln Asn
344 354 364 374 384 394 404
ATTGCTTCAC TACCCATCGG TGTCCATTTA TAGAATAATG TGGGAAGAAA CAAACCCGTT TTATGATTTA

CTCATTATCG CCTTTTGACA GCTGTGCTGT AACACAAGTA AATGCCTGAA CTTGAATTAA TCCACACATC
414 424 434 444 454 464 474

AGTAATGAT TCTATCTCTC TTTACATTTT GGTCTCTATA CTACATTATT AATGGGTTTT GTGTACTGTA
484 494 504 514 524 534 544

```

SUBSTITUTE SHEET

11 / 27

FIG. 4-2

554 564 574 584 594 604 614
AAGAAATTTAG CTGTATCAAA CTAGTGCATG AATAGATTCT CTCCTGATTA TTTATCACAT AGCCCCCTTAG

624 634 644 654 664 674 684
CCAGTTGTAT ATTATTCTTG TGGTTTGTGA CCAAAATTAAG TCCFACTTA CATATGCTTT AAGAAATCGAT

694 704 714 724 734 744 754
GGGGGATGCT TCATGTGAAC GTGGGAGTTC AGCTGCTTCT CTTCCTAAG TATTCCTTTC CTGATCACTA

764 774 784 794 804 814 824
TGCAATTTTAA AGTTAAACAT TTTTAAAGTAT TTCAGATGCT TTAGAGAGAT TTTTTTTCCA TGACIGCAAT

834 844 854 864 874 884 894
TTACTGTACA GATTGCTGCT TCTGCTATAT TTGTGATATA GGAATTAAGA GGATACACAC GTTTGTTTCT

904 914 924 934 944 954 964
TCGTGCCCTGT TTTATGTGCA CACATTAGGC ATTGAGACTT CAAGCTTTTC TTTTTTTGTC CACGTATCTT

974 984 994 1004 1014 1024 1034
TGGGTCTTTG ATAAAGAAA GAATCCCTGT TCATTGTAAG CACTTTTACG GGGCGGGTGG GGAGGGGTGC

1044 1054
TCTGCTGGTC TTCAATTACC AAGAAATTC

SUBSTITUTE SHEET

12 / 27

ATG	GAT	GCA	GAA	TTC	CGA	CAT	GAC	TCA	GGA	TAT	GAA	GTT	CAT	CAT
Met	Asp	Ala	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His
0										10				
CAA	AAA	TTG	GTG	TTC	TTT	GCA	GAA	GAT	GTG	GGT	TCA	AAC	AAA	
Gln	Lys	Leu	Val	Phe	Phe	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	
					20									
GGT	GCA	ATC	ATT	GGA	CTC	ATG	GTG	GGC	GGT	GTT	GTC	ATA	GCG	
Gly	Ala	Ile	Ile	Gly	Leu	Met	Val	Gly	Gly	Val	Val	Ile	Ala	
	30										40			
ACA	GTG	ATC	GTC	ATC	ACC	TTG	GTG	ATG	CTG	AAC	AAG	AAA	CAG	
Thr	Val	Ile	Val	Ile	Thr	Leu	Val	Met	Leu	Lys	Lys	Lys	Gln	
						50								
TAC	ACA	TCC	ATT	CAT	CAT	GGT	GTG	GTG	GAG	GTT	GAC	GCC	GCT	
Tyr	Thr	Ser	Ile	His	His	Gly	Val	Val	Glu	Val	Asp	Ala	Ala	
			60										70	
GTC	ACC	CCA	GAG	GAG	CGC	CAC	CTG	TCC	AAG	ATG	CAG	CAG	AAC	
Val	Thr	Pro	Glu	Glu	Arg	His	Leu	Ser	Lys	Met	Gln	Gln	Asn	
									80					
GGC	TAC	GAA	AAT	CCA	ACC	TAC	AAG	TTC	TTT	GAG	CAG	ATG	CAG	
Gly	Tyr	Glu	Asn	Pro	Thr	Tyr	Lys	Phe	Phe	Glu	Gln	Met	Gln	
					90									
AAC														
Asn														

FIG. 5

SUBSTITUTE SHEET

13/ 27

FIG. 6

GAA TTC GGA CAT GAT TCA GGA TTT GAA GTC CGC CAT CAA AAA CTG GTG TTC TTT	27	54
Glu Phe Gly His Asp Ser Gly Phe Glu Val Arg His Gln Lys Leu Val Phe Phe		
3	10	20
GCT GAA GAT GTG GGT TCG AAC AAC AAA GGC GCC ATC ATC GGA CTC ATG GTG GGC GGC	81	108
Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Ile Gly Leu MET Val Gly Gly		
	30	
GTT GTC ATA GCA ACC GTG	135	
Val Val Ile Ala Thr Val		
40		

SUBSTITUTE SHEET

14 / 27

FIG. 7-1 Nucleotide Comparison

W3	GAA	TTC	CGA	CAT	GAC	TCA	GGA	TAT	GAA	GTT	CAT	CAT	CAA	AAA	TTG	GTG	TTC	TTT	54
		X			X			X											
W9	GAA	TTC	GGA	CAT	GAT	TCA	GGA	TTT	GAA	GTC	CGC	CAT	CAA	AAA	CTG	GTG	TTC	TTT	54
W3	GCA	GAA	GAT	GTG	GGT	TCA	AAC	AAA	GGT	GCA	ATC	ATT	GGA	CTC	ATG	GTG	GGC	GGT	108
	X					X			X										
W9	GCT	GAA	GAT	GTG	GGT	TCG	AAC	AAA	GGC	GCC	ATC	ATC	GGA	CTC	ATG	GTG	GGC	GGC	108
W3	GTT	GTC	ATA	GCG	ACA	GTG													135
W9	GTT	GTC	ATA	GCA	ACC	GTG													135

SUBSTITUTE SHEET

15/27

FIG. 7-2

Amino Acid Comparison

W3	Glu	Phe	Arg	His	Asp	Ser	Gly	Tyr	Glu	Val	His	His	Gln	Lys	Leu	Val	Phe	Phe
			X				X											
W9	Glu	Phe	Gly	His	Asp	Ser	Gly	Phe	Glu	Val	Arg	His	Gln	Lys	Leu	Val	Phe	Phe
W3	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile	Gly	Leu	MET	Val	Gly	Gly
W9	Ala	Glu	Asp	Val	Gly	Ser	Asn	Lys	Gly	Ala	Ile	Ile	Gly	Leu	MET	Val	Gly	Gly
W3																		
W9																		

16 / 27




FIG. 8

SUBSTITUTE SHEET

FIG. 9A 1

5

3

CACCTGTCCAAGATGTCAGCAGAACGGCTACGAAATCCAACTACAAGTTCCTTGAGCAGATGCAGAACTA
CGGGTGGACAGGTTCTACGTGCTCTTGCGGATGCTTTTAGGTGGATGTTCAAGAACTCTGCTACGTCTTGATTGGA

HaeII

2

4

6

HindII

289

GlupheAsnGlyGluValCysSerGluGlnAlaGluThrGlyProCysArgAlaMetIleSerArgIrpTyrPheAspVal
AATTCAACGGCGAGGTGTCCTCTGAACAAGCTGAGACTGGCCCGTGCCGTGCAATGATCTCCGCTGGTACTTTGATGTG
GTGCGCGCTCCACACGAGACTTGTTGACTCTGACCGGGCACGGCAGCTTACTAGAGGGCGACCAATGAACACTACAC

EcoRI


ThrGluGlyLysCysAlaProPhePheTyrGlyGlyCysGlyGlyAsnArgAsnAsnAsnPheAspThrGluGluTyrCysMet
ACTGAAGGTAAGTGGCTCCATTCTTTACGGCGGTGCGCGGCAACCGTAACAACCTTTGACACACTGAAGAGTACTGCATG
TGACTTCCATTACCGGAGGTAAAGAAATGCCGCCAACGCCCGCTTGGCATTTGTTGAACCTGIGACTTCTCAIGACGTAC

345

AlaValCysGlySerAlaIleTER
GCAGTGTGGCGCAGCGCTATTAAAGGATCCA
CGTCACACGCCGTCGCGATAAATTCCTAGGTTCGA

BamHIIHindIII

FIG. 9D



SUBSTITUTE SHEET

19/ 27

FIG. 9C

NH₂-Met-Thr-Ile-Thr-Leu-Thr-Thr-Thr-Thr-Thr- (beta-gal-thr leader)
 655
 Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-
 Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-
 Ile-Ala-Thr-Val-Ile-Val-Ile-Thr-Leu-Val-Met-Leu-Lys-Lys-Lys-Gln-Tyr-Thr-Ser-
 Ile-His-His-Gly-Val-Val-Glu-Val-Asp-Ala-Ala-Val-Thr-Pro-Glu-Glu-Arg-His-Leu-
 Ser-Lys-Met-Gln-Gln-Asn-Gly-Tyr-Glu-Asn-Pro-Thr-Tyr-Lys-Phe-Phe-Glu-Gln-Met-
 751
 Gln-Asn-COOH (B-amyloid-related polypeptide)

SUBSTITUTE SHEET

20/27




FIG. 10

SUBSTITUTE SHEET

21/ 27




FIG. 11

SUBSTITUTE SHEET

22 / 27




FIG. 12

SUBSTITUTE SHEET

23/ 27

FIG. 13 - I

TIHUBI : Inter-alpha-trypsin inhibitor (BPI type)
50.0% identity in 52 aa overlap

```

1" AVLPQEEGGGQLVTEVTKKEDSCQLGYSAGPCHGMTSRYFYNGTSHACETFQYGGCH
      |
INSERT 1' EVCSEQAETGPCRAMISRWFYFDVTEGKCAPFFYGGCGGNRN
TIHUBI   :.. : : : : : : : : : : : : : : : : : : : : : : : :
61" GNGNFFVTEKECLQTCRTVAACNLPVIRGPCRAFIQLWAFDAVKGKCVLFPYGGCQGNNGN
      |
      |
42' NFDTEEYCMVCGSAI
      |
121" KFYSEKREYCGVPGDEDELL
      |

```

TIBOBI : Inter-alpha-trypsin inhibitor (BPI type) 48.1% identity in 54 aa overlap

```

INSERT 1' EV
TIBOBI 1" KADSCQLDYSQGPCCLGLFKRYFYNGTSMACETFLYGGCMGNLNNFLSQKECLQTCRTVEA
      |
      |
3' CSEQAETGPCRAMISRWFYFDVTEGKCAPFFYGGCGGNRNFDTEEYCMVCGSAI
      |
      |
61" CNLPVQGPCRAFIQLWAFDAVKGKCVRFSGGCKGNNGNKFYSQKECKEYCGIPGEADER
      |
121" LL

```

SUBSTITUTE SHEET

FIG. 13-2

**TIBO : Basic protease inhibitor precursor - Bovine
47.4% identity in 57 aa overlap**

```

INSERT      1'          EVCSEQAETGPCRAMISRWFYDVTEGKCAPFFYGGCGGNRRNFD
              . : ... ::::: : .....: ...: ::::: ..:::..
TIBO       1"    PSLFNRPPIPAAQRPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFK
              |
               45'   TEEYCMAVCGSAI
                   ..: : ..:::~
               61"   SAEDCMRTCGGAIGPWGKTGGRAEGEGKG
                   |

```

**TIBOR : Serum basic protease inhibitor - Bovine
42.9% identity in 56 aa overlap**

INSERT 1' EVCSEQAETGPCRAMISRWFYFDVTEGKCAPFFYGGCGNRNFDTEEYCMAVCGSA
TIBOR 1" TERPDFCLEPPYTGPCKAAMIRYFYNAKAGFCETFYGGCRAKSNNFKSAEDCMRTCGGA
57' I





FIG. 14

SUBSTITUTE SHEET

26 / 27

CV-1 CELLS INFECTED
WITH A4₇₅₁-VACCINIA VIRUS
Western Blot




FIG. 15

SUBSTITUTE SHEET

27/ 27

A.

NdeI

TATG AAA AAG ACA GCT ATC GCG ATT GCA GTG GCA CTG GCT GGT TTC GCT ACC
 TAC TTT TTC TGT CGA TAG CGC TAA CGT CAC CGT GAC CGA CCA AAG CGA TGG
 Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala Thr
 10

GTA GCG CAG GCC*GAG GTG TGC TCT GAA CAA GCT GAG ACT GGC CCG TGC CGT GCA
 CAT CGC GTC CGG CTC CAC ACG AGA CTT GTT CGA CTC TGA CCG GGC ACG GCA CGT
 Val Ala Gln Ala Glu Val* Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala
 20 30

ATG ATC TCC*CGC TGG TAC TTT GAT GTG ACT GAA GGT AAG TGC GCT CCA TTC TTT
 TAC TAG AGG GCG ACC ATG AAA CTA CAC TGA CTT CCA TTC ACG CGA GGT AAG AAA
 Met Ile Ser Arg Trp* Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 40 50

TAC GGC GGT TGC GGC GGC AAC CGT AAC AAC*TTT GAC ACT GAA GAG TAC TGC ATG
 ATG CCG CCA ACG CCG CCG TTG GCA TTG TTG AAA CTG TGA CTT CTC ATG ACG TAC
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp* Thr Glu Glu Tyr Cys Met
 60 70

BamHI

GCA GTG TGC GGC AGC GCT ATT TAA GGATCCA
 CGT CAC ACG CCG TCG CGA TAA ATT CCTAGGTTCTGA
 Ala Val Cys Gly Ser Ala Ile HindIII

B.

NdeI

TATG AAA CAA AGC ACT ATT GCA ATG GCA CTC TTA CCG TTA CTG TTT ACC CCT
 TAC TTT GTT TCG TGA TAA CGT TAC CGT GAG AAT GGC AAT GAC AAA TEG GGA
 Met Lys Gln Ser Thr Ile Ala Met Ala Leu Leu Pro Leu Leu Phe Thr Pro
 10

GTG ACA AAA GCC*GAG GTG TGC TCT GAA CAA GCT GAG ACT GGC CCG TGC CGT GCA
 CAC TGT TTT CGG CTC CAC ACG AGA CTT GTT CGA CTC TGA CCG GGC ACG GCA CGT
 Val Thr Lys Ala Glu Val* Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala
 20 30

ATG ATC TCC*CGC TGG TAC TTT GAT GTG ACT GAA GGT AAG TGC GCT CCA TTC TTT
 TAC TAG AGG GCG ACC ATG AAA CTA CAC TGA CTT CCA TTC ACG CGA GGT AAG AAA
 Met Ile Ser Arg Trp* Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe
 40 50

TAC GGC GGT TGC GGC GGC AAC CGT AAC AAC*TTT GAC ACT GAA GAG TAC TGC ATG
 ATG CCG CCA ACG CCG CCG TTG GCA TTG TTG AAA CTG TGA CTT CTC ATG ACG TAC
 Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp* Thr Glu Glu Tyr Cys Met
 60 70

BamHI

GCA GTG TGC GGC AGC GCT ATT TAA GGATCCA
 CGT CAC ACG CCG TCG CGA TAA ATT CCTAGGTTCTGA
 Ala Val Cys Gly Ser Ala Ile HindIII

FIG. 16

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No **PCT/US90/03143**

I. CLASSIFICATION F SUBJECT MATTER (if several classification symbols apply, indicate all) ³ According to International Patent Classification (IPC) or to both National Classification and IPC <div style="display: flex; justify-content: space-between;"> IPC (5): A61K 37/64; C07K 7/10 U.S. CL.: 530/326; 514/12 </div>						
II. FIELDS SEARCHED <div style="text-align: center; margin-top: 10px;">Minimum Documentation Searched ⁴</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 25%; padding: 5px;">Classification System</td> <td style="padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="text-align: center; padding: 10px;">US</td> <td style="text-align: center; padding: 10px;">530/326, 514/12</td> </tr> </table> <div style="text-align: center; margin-top: 10px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵</div>			Classification System	Classification Symbols	US	530/326, 514/12
Classification System	Classification Symbols					
US	530/326, 514/12					
Sequence Search (Swiss-pnot, PIR, CAS registry), Chemical Abstract Service, Automated Patent Search						
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴						
Category [*]	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸				
$\frac{X}{Y}$	Nature "Protease Inhibit domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease." volume 331, page 528-530. Tanzi et al., 11 February 1988. See figure 2.	1,4,6,8,10,17, 24, 31 <u>11-14, 18-21,</u> 25-28, 32-35				
$\frac{X}{Y}$	Nature "Novel precursor of Alzheimer's disease amyloid protein shows protease inhibitory activity" volume 331, page 530-532. Kitaguchi et al., 11 February 1988. See figure 2.	1,4,6,8,10,17 24, 31 <u>11-14, 18-21,</u> 25-28, 32-35				
$\frac{X}{Y}$	Nature "A new A4 amyloid mRNA contains a domain homologous to serine protease inhibitors". volume 331, pages 525-527. Ponte et al., 11 February 1988 See Figure 1.	1,4,6,8,10,17 24, 31 <u>11-14, 18-21,</u> 25-28, 32-35				
$\frac{A}{Y}$	Nature "Enter a proteinase inhibitor" volume 331, page 478-479. Correll, 11 February 1988. See entire article	1-10, 15-17, 22-24, 29-31, 36-37 <u>11-14, 18-21,</u> 25-28, 32-35				
A	US, A, 4,666,829 (GLENNER ET AL) 19 May 1987, See entire document	1-37				
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>[*] Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"d" document member of the same patent family</p> </div> </div>						
IV. CERTIFICATION						
Date of the Actual Completion of the International Search ¹ <div style="text-align: center; font-weight: bold; font-size: 1.2em;">18 JULY 1990</div>	Date of Mailing of this International Search Report ² <div style="text-align: center; font-weight: bold; font-size: 1.5em;">22 OCT 1990</div>					
International Searching Authority ¹ <div style="text-align: center; font-weight: bold; font-size: 1.2em;">ISA/US</div>	Signature of Authorized Officer ²⁰ <div style="text-align: center;"> NINA OSSANNA, Ph.D. </div>					

Form PCT/ISA/210 (second sheet) (May 1986)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
A,P	US, A, 4,912,206 (GOLDGABER ET AL) 27 March 1990 See entire patent.	1-37
Y	US, A, 4,595,674 (TSCHESCHE ET AL) 17 June 1986 See Table 2.	11-14,18-21, 25-28, 32-35